ORIGINAL ARTICLE

Detection of Some Virulence Factors from *Candida* spp. Isolated from Vaginal and Oral Candidiasis in Iraqi Patients

Sara S. Maryoush, Hamzia A. Ajah, Raghad A. Abdulrazaq

Department of Biology, College of Science, Al-Mustansiriyah University, Baghdad, Iraq

SUMMARY

Background: Candidiasis can be present as a cutaneous, mucosal, or deep-seated organ infection, which is caused by more than 20 types of *Candida* spp., with *C. albicans* being the most common. Hence, this work aimed to estimate some virulence factors, including phospholipase and biofilm formation, in some *Candida* spp.

Methods: A total of eighty-six specimens were collected from patients with oral and vaginal candidiasis and subjected into different examinations, including cultural characteristic (on Sabouraud Dextrose Agar SDA and chromogenic *Candida* agar) and microscopic examination and germ tube formation (GT)to isolate *Candida* spp. In addition, the egg-yolk agar plate method was used to determine the extracellular phospholipase production, and the microtiter plate method was used to determine biofilm formation of *Candida* spp. Vitek Compact equipment was used to identify the highest phospholipase and biofilm-producers of *Candida* spp.

Results: As a result of all examinations, 58.1% (n = 50/86) of isolates of *Candida* spp. were obtained, including 26.7% (n = 23/86) isolates of *Candida* spp. from oral cavity and 31.3% (n = 27/86) isolates of *Candida* spp. from vaginal cavity. These isolates included 58% (n = 29/50) *C. albicans*, 10% (n = 5/50) *C. glabrata*, 6% (n = 3/50) *C. parasilosis*, 6% (n = 3/50) *C. krusei*, 6% (n = 3/50) *C. lusitaniae*, 6% (n = 3/50) *C. kefyr*, 6% (n = 3/50) *C. tropicalis*, and 2% (n = 1/50) *C. ciferrii*. To quantify extracellular phospholipase production, the egg-yolk agar plate method was utilized. The results indicated that the majority of isolates (n = 33; 66%) were phospholipase-strong producers, 18% (n = 9) of isolates were phospholipase-moderate producers, 5% (n = 10) were phospholipase-weak producers, and 6% (n = 3) were non-phospholipase producers. Microtiter plate method was utilized to estimate formation of biofilm by *Candida* spp. obtained from vaginal and oral cavities. The majority of *Candida* spp. isolates (n = 32; 64%) were biofilm-strong producers, followed by 30% (n=15) moderate-biofilm producers and 6% (n = 3) weak-biofilm producers. The results of VITEK 2 system indicated that the probability of *C. albicans*, *C. krusei*, *C. kefyr*, *C. tropicalis*, *C. lusitaniae*, *C. glabrata*, and *C. ciferrii* was 98, 95, 94, 91, 85, 93, and 85 %, respectively. *Conclusions: Candida albicans* was the most frequent isolate among all isolates.

(Clin. Lab. 2025;71:xx-xx. DOI: 10.7754/Clin.Lab.2024.240304)

Correspondence:

Sara Salim Maryoush Department of Biology College of Science Al-Mustansiriyah University Baghdad Iraq Email: sarahsalim670@gmail.com

KEYWORDS

Candida spp., phospholipase production, candidiasis, virulence factors

LIST OF ABBREVIATIONS

VVC - Vulvovaginal candidiasis T2DM - Type 2 diabetes mellitus SDA - Enriched Sabourauddextrose agar KOH - Potassium hydroxide GT - Germ tube

Manuscript accepted June 4, 2024

YPD - Yeast peptone dextrose PBS - Phosphate-buffered saline

INTRODUCTION

There are more than 20 different forms of *Candida* spp., with *C. albicans* being the most prevalent, and they may all cause candidiasis, which can manifest as a cutaneous, mucosal, or deep-seated organ infection. This pathogenic yeast is often found in the wholesome microbiome [1]. Candidiasis includes different types, such as vulvovaginal and oral candidiasis. Congenital candidiasis may result from a mother's case of vulvovaginal candidiasis (VVC), which is frequent in the latter months of pregnancy. VVC infections can also lead to miscarriage or premature birth [2,3].

Candida spp. vaginal infections, the second most frequent kind of illness, produce severe vulvovaginal candidiasis in most women. An overgrowth of the fungus Candida, most often Candida albicans, causes oral candidiasis, a frequent opportunistic infection of the mouth. The prevalence changes with age and other risk variables [4]. Candida albicans is the most prevalent species in colonization of the oral mucosa in healthy and immunocompromised individuals. In addition, Candida albicans was the most frequent fungus isolated from type 2 diabetes mellitus(T2DM) in Iraqi patients [5]. Nevertheless, C. dubliniensis, C. guilliermondii, C. krusei, C. glabrata, C. tropicalis, and C. parapsilosis have also been reported [6]. In order to produce disease, Candida spp. need some virulence factors to invade the host and survive, including biofilm formation and phospholipases [7,8].

Biofilms are populations of microorganisms that are commonly connected to a surface and wrapped in an extracellular polysaccharide matrix created by the bacteria. The four secreted phospholipases A through D (PLA, PLB, PLC, and PLD) hydrolyze one or more ester bonds of glycerophospholipids on the host cell membrane and are hence crucial players in tissue invasion. These enzymes are responsible for the breakdown of cell membranes and may break down a broad range of host cell proteins such as cytokines, complements, collagen, keratin, antibodies, and mucus [9].

The objectives of the present study were to investigate biofilm formation and phospholipase production from some isolates of *Candida* spp. obtained from Iraqi patients with vaginal and oral candidiasis.

MATERIALS AND METHODS

Isolation of *Candida* isolates

Eighty-six specimens were collected from patients with oral and vaginal candidiasis who attended the AL-Baladi Teaching Hospital during the period from November 2022 to May 2023. These specimens included fortyeight vaginal and forty oral swabs. All specimens, including 40 oral cavity swabs and 46 vaginal cavity swabs, were collected and transported under aseptic conditions to the laboratory. Then, all specimens were cultured on chloramphenicol (250 mg/L) enriched-Sabouraud dextrose agar (SDA) (Himedia/India) and incubated for 48 hours at 37°C under aerobic conditions.

Identification of *Candida* isolates Cultural examination

Using SDA, the cultural characteristics, including size, texture, color, shape, opacity, and margin of colonies, were investigated. Then, the Candida spp. isolates were recultured on selective and differential medium, called chromogenic Candida agar (Himedia/India), for 48 hours at 37°C. After incubation, the color of colonies was utilized as indicator for identification of yeast. CHROMagar Candida is a ready-to-use chromogenic medium that distinguishes C. krusei, C. tropicalis, and C. albicans based on colony color and shape. C. albicans colonies are light to medium green, C. tropicalis colonies appear dark blue to metallic blue, and C. krusei and C. lusitaniae colonies are pink with a white border. Other yeasts, such as C. glabrata, can generate either light to dark mauve or cream hues on isolation media. Colonies of C. ciferrii develop well, are regular spherical with a blue center and white edge, and become rough with gyrus-like grooves and uneven edges [6,10].

Microscopic examination

The isolates were also stained with Gram stain after being placed on a clean slide with a drop of physiological saline and were examined under microscope [10]. Furthermore, a section of the colony was checked with a sterile stick and deposited on a clean slide, which was then mixed with a drop of lactophenol cotton blue, coated with a cover slip, and tested under a light microscope [10].

Germ tube formation (GT)

Germ tube formation by *Candida* spp. isolates was studied by transferring a small portion of colonies using a sterile stick, mixing with 0.5 mL of human serum, and incubating the mixture at 37° C for 2.5 hours. Other yeast species tend to form germ tubes during incubation, therefore keeping the incubation time under 3 hours is essential. Drops of the cultured serum were placed on microscope slides using a pasteur pipette, and any germ tubes that formed were counted. The human serum was prepared based on the method described by Yin et al. [11]. The detection and distinction of *Candida* spp. was performed after 48 hours of incubation at 45° C.

Detection of some virulence factors of *Candida* spp. Extracellular phospholipase production

To quantify extracellular phospholipase production, the egg yolk agar plate method was utilized. Ten microliters of fresh inoculum of *Candida* (containing 24-hour-old colonies re-suspended in five milliliters of sterile nor-

mal saline with 1.5×10^8 CFU/mL) was added into egg yolk agar medium. The plates were placed into an incubator for 48 hours at 37°C. The opacity zone's diameter and the colonies' diameters were estimated to calculate the value of phospholipase (Pz) with the following equation [12]:

 $Pz = \frac{The colony diameter (a)}{The diameter of colony + Precipitation zone (b)}$

The results are illustrated in Table 1.

Table 1. The ranges used to evaluate phospholipase activity.

Value of Pz	Phospholipase activity
1	Negative
0.80 - 0.89	Weak
0.70 - 0.79	Moderate
< 0.70	Strong

Biofilm formation

The formation of biofilm was estimated using polystyrene 96-well microplates. Two milliliters of broth of yeast peptone dextrose (YPD) were utilized to culturing Candida spp. for 24 hours at 37°C. Serial dilution was performed to obtain 1:20 Candida-cultured broth of YPD as a final solution. Each well plate was filled with two hundred microliters of Candida-cultured YPD broth, except for the control wells, which filled with 200 µL of fresh YPD. A lid was used to seal the plate. The plate was placed into an incubator for 24 hours at 37°C. Then, the media in the wells was discarded and the plate was cleaned twice using sterile phosphate buffer saline (PBS) to eliminate any unbonded cells. The plate was left for fifteen minutes at room temperature. Then, 200 µL of crystal violet were filled into each well, and the plate was left to stand for twenty minutes. The content of the wells was discarded by using PBS three times in order to eliminate unattached stain, and the plate was left to dry at room temperature. Two microliters of solution (20:80 v/v; acetone:ethanol) were filled in each well. ELISA reader was utilized to read the OD at 450nm. The results were determined as described by Tartor et al., 2022 [13], as shown in Table 2.

Table 2. The values used to evaluate biofilm formation.

Value of OD	Formation of biofilm
> 0.320	Strong
0.120 - 0.320	Moderate
< 0.120	Weak

VITEK 2 system identification of Candida spp.

The Vitek Compact equipment, manufactured by bio-Merieux Inc. in Durham, NC 27712, USA, was used to identify Candida spp. in accordance with the manufacturer's protocol. To meet the standards set out in 21 CFR sections 11, which deal with electronic records and signatures, these protocols incorporate the Vitek Compact instrument. Each of the reagent cards has 64 wells, and those wells are specifically made to hold a specific kind of test substrate. Acidification, alkalinization, enzyme hydrolysis, and compound formation are just a few of the many metabolic activities that may be quantified using substrates in the presence of inhibitory substances. An optically clear covering coats both sides of the card, which together form a sealed vessel that prevents oxygen delivery from interacting with the substrate admixtures of the organism. Inserting the card into the device reveals information about the product's category, lot number, expiration date, and sample's unique identification through the bar codes on the outside.

RESULTS

Figure 1 shows the color of the colonies; each colored colony indicated presence of specific species of *Candida*. Colonies of *C. albicans* appeared as light green colonies, while the fuzzy, purple colonies indicated presence of *C. krusei*.

As a result of all examinations, 58.1% (n = 50/86) of isolates of *Candida* spp. were obtained, including 26.7% (n = 23/86) isolates of *Candida* spp. from oral cavity and 31.3% (n = 27/86) isolates of *Candida* spp. from vaginal cavity. These isolates include 58% (n = 29/50) *C. albicans*, 10% (n = 5/50) *C. glabrata*, 6% (n = 3/50) *C. parasilosis*, 6% (n = 3/50) *C. krusei*, 6% (n = 3/50) *C. tropicalis*, and 2% (n = 1/50) *C. ciferrii*, as shown in Figure 2.

Production of phospholipase enzyme was estimated among isolates of *Candida* spp. by using egg yolk agar plate method, whereas the results indicated that the majority of isolates (n = 33; 66%) were phospholipasestrong producers, 18% (n = 9) of isolates were phospholipase-moderate producers, 5% (n = 10) were phospholipase-weak producers, and 6% (n = 3) were non-phospholipase producers, as mentioned in Tables 3 and 4. Microtiter plate method was utilized to estimate formation of biofilm by *Candida* spp. obtained from vaginal and oral cavities. Based on the Tables 5 and 6, the majority of isolates (n = 32; 64%) were biofilm-strong producers, followed by 30% (n = 15) moderate-biofilm producers.

VITEK 2 system identification of Candida spp.

According to the manufacturer's protocol, Vitek Compact equipment was used to identify *Candida* spp., as represented in Figures3 A, B, C, D, E, F, and G. The re-

Candida spp. (CV)	Pz value	Candida spp. (CO)	Pz value
C. albicans CV1	0.52	C. albicansCO28	0.41
C. albicans CV2	0.57	C. albicansCO29	0.75
C. albicans CV3	0.77	C. albicansCO30	0.82
C. albicans CV4	0.48	C. albicansCO31	0.55
C. albicans CV5	0.46	C. albicansCO32	0.64
C. albicans CV6	0.35	C. albicansCO33	0.52
C. albicans CV7	0.49	C. glabrataCO34	0.32
C. albicans CV8	0.76	C. glabrataCO35	-
C. albicans CV9	0.55	C. glabrataCO36	0.81
C. albicans CV10	0.82	C. glabrataCO37	0.54
C. albicans CV11	0.56	C. glabrataCO38	0.36
C. albicans CV12	0.85	C. kruseiCO39	0.32
C. albicans CV13	0.33	C. kruseiCO40	0.71
C. albicans CV14	0.49	C. kruseiCO41	0.46
C. albicans CV15	0.54	C. lusitaniaeCO42	0.73
C. albicans CV16	0.50	C. lusitaniaeCO43	0.72
C. albicans CV17	0.72	C. kefyrCO44	-
C. albicans CV18	0.62	C. kefyrCO45	0.35
C. albicans CV19	0.44	C. kefyrCO46	0.86
C. albicans CV21	0.54	C. tropicalisCO48	0.74
C. albicans CV20	0.63	C.tropicalisCO47	0.73
C. albicans CV22	0.35	C. tropicalisCO49	0.46
C. albicans CV23	0.42	C. ciferriiCO50	0.43
C. parasilosis CV24	-		
C. parasilosis CV25	0.43		
C. parasilosis CV26	0.49		
C. lusitaniae CV27	0.54		

Table 3. Phospholipase values of vaginal and oral Candida spp.

* CV - Candida species isolated from vagina, CO - Candida species isolated from oral cavity.

Table 4. The degree of phospholipase production in vaginal and oral Candida spp.

Isolate source		Phospholipas	se production		Total
isolate source	negative	weak	moderate	strong	Total
Oral isolates	2 (4%)	3 (6%)	6 (12%)	12 (24%)	23 (46%)
Vaginal isolates	1 (2%)	2 (4%)	3 (6%)	21 (42%)	27 (54%)
Total	3 (6%)	5 (10%)	9 (18%)	33 (66%)	50 (100%)

sults indicated that the probability of *C. albicans*, *C. krusei*, *C. kefyr*, *C. tropicalis*, *C. lusitaniae*, *C. glabrata*, and *C. ciferrii* was 98, 95, 94, 91, 85, 93, and 85%, respectively.

DISCUSSION

The size, texture, color, shape, opacity, and margin colonies were estimated on SDA. The results revealed that some colonies appeared as yeast-like, smooth with

Candida spp. (CV)	OD value	Candida spp. (CO)	OD value
C. albicans CV1	1.041	C. albicansCO28	0.904
C. albicans CV2	0.123	C. albicansCO29	0.524
C. albicans CV3	0.121	C. albicansCO30	0.233
C. albicans CV4	0.832	C. albicansCO31	0.420
C. albicans CV5	1.152	C. albicansCO32	1.395
C. albicans CV6	1.342	C. albicansCO33	0.780
C. albicans CV7	0.451	C. glabrata CO34	1.125
C. albicans CV8	0.823	C. glabrata CO35	0.90
C. albicans CV9	0.071	C. glabrata CO36	0.240
C. albicans CV10	0.301	C. glabrata CO37	0.493
C. albicans CV11	0.081	C. glabrataCO38	1.230
C. albicans CV21	0.093	C. kruseiCO39	0.561
C. albicans CV13	0.395	C. kruseiCO40	0.311
C. albicans CV14	0.672	C. kruseiCO41	1.831
C. albicans CV15	0.525	C. lusitaniaeCO42	0.192
C. albicans CV16	0.185	C. lusitaniaeCO43	0.816
C. albicans CV17	0.875	C. kefyrCO44	0.190
C. albicans CV18	0.380	C. kefyrCO45	0.730
C. albicans CV19	0.141	C. kefyrCO46	0.267
C. albicans CV20	0.183	C. tropicalisCO47	0.584
C. albicans CV21	0.530	C. tropicalisCO48	0.344
C. albicans CV22	0.301	C. tropicalisCO49	1.141
C. albicans CV23	0.966	C. ciferriiCO50	1.240
C. parasilosis CV24	0.251		
C. parasilosis CV25	0.175		
C. parasilosis CV26	1.131		
C. lusitaniae CV27	0.820		

Table 5. The biofilm OD of vaginal and oral Candida spp.

* CV - Candida species isolated from vagina, CO - Candida species isolated from oral cavity, Pz - Phospholipase.

Isolate source		Biofilm formation		Total
isolate source	weak	moderate	strong	Total
Oral isolates	0 (0%)	6 (12%)	17 (34%)	23 (46%)
Vaginal isolates	3 (6%)	9 (18%)	15 (30%)	27 (54%)
Total	3 (6%)	15 (30%)	32 (64%)	50 (100%)

white color, which expected to be colonies of *C. albicans*, while some colonies observed as smooth, shiny, and creamy with white color, which expected to be colonies of *C. parapsilosis*. Also, colonies of *C. glabrata*, *C. kefyr*, *C. ciferii*, and *C. tropicalis* appeared as

smooth, glossy, and cream-colored, while *C. krusei* shows rough colonies on this medium; these results correspond with a previous study conducted by Al-Dabbagh et al., 2023 [10].




Figure 1. Candida spp. growth on CHROMagar Candida (CaC) (24 hours/37°C).

a) C. albicans; b) C. krusei; c) C. glabrata; d) C. kefyr; e) C. tropicalis; f) C. parasilosis, and j) C.ciferrii.




Figure 2. The distribution of *Candida* spp. among the samples.

The colony morphology of *Candida* species can be used to distinguish them from other organisms when using chromogenic Candida agar, which is a differential and selective medium that facilitates the quick separation of *Candida* from mixed culture. *Candida* spp., specifically *C. albicans* and *C. glabrata*, produce specific enzymes that react only with the chromogenic Candida agar's reactive substrate [14].

According to Figure 1, each colored colony indicated the presence of specific species of *Candida*. Colonies of *C. albicans* appeared as light green colonies, while the fuzzy and purple colonies indicated the presence of *C*.

|
 |
 | | | ology Cha |
 | | |
 | |
 | |
 | | | | | | ted Februar | |
 |

--|--|--|--
---|---|--
--
--	--
--	---
---	--
bioMérieux Customer: Patient Name: v27 Location:	
 | А
 | $\left \right $ | Microbic | 8, 11 | arreport
 | | Time Teora | Patien
 | t:52:22 PM AST
t ID: EWGTEV
Physician:
olate Number: 1 | bioMérieux Custor
Patient Name:
Location:
 | mer: | В
 | | licrobiolog | y Chart R | eport | | | Patier | nt ID: 1
iolate ?
 |
| Lab ID: 75
Organism Quantity:
 |
 | | | |
 | | | ls
 | orane retunnder: 1 | Lab ID: 77
Organism Quantity:
 | |
 | | | | | | | ls | -mate
 |
| Selected Organism : Candida
Source:
 | la albicans
 | | | |
 | | |
 | Collected: | Selected Organism :
Source:
 | Candida k | krusei
 | | | | | | | |
 |
| Comments:
 | <u> </u>
 | | | |
 | | |
 | | Comments:
 | - |
 | | | | | | | | _
 |
|
 |
 | | | |
 | | |
 | |
 | |
 | | | | | | | |
 |
| Identification Information
 | 1
 | 0 | Analysis Time | | 17.80 hours
 | | Status: | Fi
 | nal | Identification Info
 | ormation |
 | | sis Time: | | 0 hours | | Status: | Fi | nal
 |
| Selected Organism
 |
 | | 98% Probabili
Bionumber: | ity | Candida all
650254606
 | | |
 | | Selected Organism
 | m |
 | | Probability
mber: | | dida krusei
254606532 | | | |
 |
| ID Analysis Messages
 |
 | | | |
 | | |
 | | ID Analysis Mess
 | ages |
 | | | | | | | |
 |
| Biochemical Details
 |
 | | | |
 | | |
 | | Biochemical Deta
3 LysA
 | | IMLTa +
 | L. L. | uA + | 7 AR | | 10 E | RYa - | 12 | GLYL
 |
| 3 LysA - 4
13 TyrA - 14
 | IMLTa
BNAG
 | + 5 | LeuA
ARBa | + 7 | ARG
AMYa
 | + 10 | ERYa - |
 | GLYLa +
GENa • | 13 TyrA
 | + 14 | BNAG -
 | 15 A | RBa - | 18 AM | Ya - | 19 d0 | GALa - | 20 | GENa
 |
| 21 dGLUa + 23
29 dRAFa - 30
 |
 | - 24
+ 32 | MAdGa
dMNEa | + 26 | dCELa
dMELa
 | - 27
- 34 | GGT - |
 | IMALa +
SBEa - | 21 dGLUa
29 dRAFa
 | + 23 | LACa -
NAGAI -
 | | AdGa -
dNEa + | 26 dCE
33 dM | | | GT -
MLZa - | | IMAL
ISBEa
 |
| 39 IRHAa - 40
47 dTURa + 48
 |
 | + 42 | dSORa | + 44 | SACa
 | + 45 | URE - |
 | AGLU + | 39 IRHAa -
47 dTURa -
 | | XLTa -
dTREa -
 | | iORa -
D3a - | 44 SAG
51 IAR | | | RE -
GATa - | | AGLU
ESC
 |
| 47 dTURa + 48
54 lGLTa + 55
 |
 | + 49
+ 56 | NO3a
LATa | - 51
+ 58 | IARAa
ACEa
 | - 52
+ 59 | dGATa - | 53 E
 | ESC -
GRTas + | 54 IGLTa
 | + 55 | dXYLa -
 | 56 L | ATa + | 58 AC | Ea + | | ITa - | | GRTas
 |
| 61 IPROa + 62
 | 2KGa
 | + 63 | NAGa | + 64 | dGNTa
 | + | |
 | | 61 IPROa
 | + 62 | 2KGa -
 | 63 N | AGa + | 64 dG? | vTa - | | | |
 |
| bioMérieux Customer:
Patient Name:
 | C
 | , | Microbi | ology Ch | art Report
 | | Printed Febru |
 | 3:12:11 PM AST
nt ID: EWGTEV | bioMérieux Custon
Patient Name: 19
 | ner: | D
 | N | licrobiolog | gy Chart F | leport | Pri | inted Febru | aary 3, 202
Pat | 3 2:30
ient ID
 |
| Location:
Lab ID: 5
 |
 | | | |
 | | | 1
 | Physician:
solate Number: | Location:
Lab ID: 3
 | |
 | | | | | | | | olate N
 |
| Organism Quantity:
Selected Organism : Candida
 | la kefyr
 | | | |
 | | |
 | | Organism Quantity:
ielected Organism : 0
 | Candida tro | opicalis
 | | | | | | | |
 |
| Source:
 |
 | | | |
 | | |
 | Collected: | iource:
 | |
 | | | | | | | |
 |
| Comments:
 |
 | | | |
 | | |
 | | Comments:
 | F |
 | | | | | | | |
 |
|
 |
 | | | |
 | | |
 | |
 | |
 | | | | | | | |
 |
| Identification Information
Selected Organism
 | 1
 | | Analysis Time
94% Probabil | | 17.90 hour
Candid
 | a kefyr | Status: | F
 | inal | Identification Infor
 | |
 | _ | sis Time:
Probability | | 00 hours
Candida t | tropicalie | Status: | | Final
 |
| ID Analysis Messages
 |
 | | Bionumber: | | 68932460
 | 65327500 |) |
 | | Selected Organism
 | |
 | Biom | | | Candida 1
943565321 | | | |
 |
| Biochemical Details
 |
 | | | |
 | | |
 | | ID Analysis Messa
 | |
 | | | | | | | |
 |
| 3 LysA - 4
 | IMLTa
 | + 5 | LeuA | + 7 | ARG
 | (-) 10 | |
 | GLYLa - | Biochemical Detail
 | | IMLTa +
 | 5 L | ruA + | 7 AF | tG + | 10 | ERYa | - 12 | GLY
 |
| 13 TyrA - 14
21 dGLUa + 23
 |
 | - 15
+ 24 | | - 18
- 26 | AMYa
dCELa
 | - 19
- 27 | | + 20
+ 28
 | GENa -
dMALa - | 13 TyrA -
21 dGLUa +
 | _ | BNAG -
 | - | RBa - | | fYa -
ELa - | - | dGALa
GGT | + 20 | GEN
 |
| 29 dRAFa + 30
39 lRHAa - 40
 |
 | - 32
+ 42 | | + 33 | dMELa
SACa
 | - 34
+ 45 | | - 38
- 46
 | ISBEa - | 29 dRAFa -
 | 30 | NAGA1 -
 | 32 d1 | dNEa + | 33 dM | IELa - | 34 | dMLZa | + 38 | ISBI
 |
|
 |
 | | | |
 | | |
 | | 39 IRHAa -
 | _ | XLTa -
 | 42 d | iORa + | 44 SA | Ca + | 45 | URE | - 46 |
 |
| 47 dTURa - 48
 |
 | + 49 | | - 51 | IARAa
 | + 52 | | + 53
 | ESC - | 47 dTURa +
 | 48 4 | dTREa +
 | 49 N | 03a - | 51 IAI | RAa (+ | _ | | + 53 | -
 |
| 54 IGLTa + 55 61 IPROa - 62 bioMérieux Customer: Patient Name: 18 Location: Lab ID: 4 roganism Quantity: -
 | dXYLa
2KGa
 | - 56
- 63 | LATa | + 58
- 64 | ACEa
dGNTa
 | + 59
- | | - 60
3, 2023 2:3
Patient I
 | GRTas (+) | 47 dTURa +
54 IGLTa +
61 IPROa +
bioMérieux Customer:
Patient Name: V47
Location:
Lab ID: 20
 | 55
62 | dTREa +
dXYLa +
2KGa +
F
 | 56 L
63 N | O3a -
ATa -
AGa +
robiology | 58 AG
64 dG | NTa + | ·) 52 (
59 (| dGATa
CITa
d February | Patient | ESC
GRT
:30:42
:1D: E ^V
P
 |
| 54 IGLTa + 55 61 IPROa - 62 bioMérieux Customer: Patient Name: 18 Location: Lab ID: 4 -
 | dXYLa
2KGa
 | - 56
- 63 | LATa
NAGa | + 58
- 64 | ACEa
dGNTa
 | + 59
- | CITa | - 60
3, 2023 2:3
Patient I
 | GRTas (+)
2:12 PM AST
D: EWGTEV
Physician: | 54 IGLTa + 61 IPROa + bioMérieux Customer: - - Patient Name: V47 Location: -
 | 62 | dXYLa +
2KGa +
F
 | 56 L
63 N | ATa -
AGa + | 58 AC
64 dG | Ea +
NTa + | ·) 52 (
59 (| dGATa
CITa | + 60
7 3, 2023 2
Patient | ESC
GRT
:30:42
t ID: E
Pl
te Num
 |
| 54 IGLTa + 55 61 IPROa - 62 bioMérieux Customer: Patient Name: 18 Location: Lab ID: 4
 | dXYLa
2KGa
 | - 56
- 63 | LATa
NAGa | + 58
- 64 | ACEa
dGNTa
 | + 59
- | CITa | - 60
3, 2023 2:3
Patient I
 | GRTas (+)
2:12 PM AST
D: EWGTEV
Physician:
Number: 1 | 54 IGLTa + 61 IPROa + bioMérieux Customer: Patient Name: V47 Location: Lab ID: 20 Dreanism Obantity: -
 | 62 | dXYLa +
2KGa +
F
 | 56 L
63 N | ATa -
AGa + | 58 AC
64 dG | Ea +
NTa + | ·) 52 (
59 (| dGATa
CITa | + 60
7 3, 2023 2
Patient | ESC
GRT
:30:42
t ID: E
Pl
te Num
 |
| 54 IGLTa + 55 61 IPROa - 62 bioMérieux Customer: Patient Name: 18 Location: Lab ID: 4
 | dXYLa
2KGa
 | - 56
- 63 | LATa
NAGa
Microbiol | + 58
- 64 | ACEa
dGNTa
t Report
 | + 59
- Pr | CITa | - 60
3, 2023 2:3
Patient I
 | GRTas (+)
2:12 PM AST
D: EWGTEV
Physician:
Number: 1
Collected: | 54 IGLTa 61 IPROa bioMéricux Customer: Patient Name: V47 Location: Lab ID: 20 Organism Quantity: Selected Organism : Car Source:
 | - 55 62 :
62 :
ndida glabri | dXYLa +
2KGa +
F
 | 56 L
63 N | ATa -
AGa +
robiology | 58 AC
64 dG | TEa +
NTa + |) 52 (
59)
Printe | dGATa
CITa | + 60
7 3, 2023 2
Patient | ESC
GRT
:30:42
t ID: E
Pl
le Num
 |
| 54 VGLTa + 55 BindPitos - 62 Bindrines Testin Nune: 18 - 62 Batterines Lacation: - 62 Lacation: Lacation: - 62 Lacation: Lacation: - 62 Lacation: Lacation: - 62 Generative: Commonth: - Commonth: Selected Organism Selected Organism Selected Organism
 | dXYLa
2KGa
 | - 56
- 63 | LATa
NAGa
Microbiol | + 58
- 64 | ACEa
dGNTa
t Report
 | + 59
- Pr | CITa
CITa | - 60
3, 2023 2:3
Patient I
Isolate
 | GRTas (+)
2:12 PM AST
D: EWGTEV
Physician:
Number: 1
Collected: | 54 IGLTa + 61 IPROa + bioMéricax Customer - - Patient Name: V47 Location: - Lab ID: 20 - - - Valation: - - - - Selected Organism : Carlource: - - - -
 | - 55 62 :
62 :
ndida glabri | dXYLa +
2KGa +
F
 | 56 L
63 N
Mic | ATa -
AGa +
robiology /
Time:
bability | S8 AC
64 dG
Chart Rep
18-20
Ca | TEa +
NTa + |) 52 59 Frinte | dGATa
CITa
d February | + 60
(3, 2023 2
Patient
Isolat | ESC
GRT
:30:42
t ID: E
P
te Num
 |
| 54 SGLTD 4 55 61 IPION - 62 bioM/bries Marine 62 bioMore Imin Imin Commentia Imin Confidenciation Selected Organism Selected Organism III Analysis Messages
 | dXYLa
2KGa
 | - 56
- 63 | LATa
NAGa
Microbiol | + 58
- 64 | ACEa
dGNTa
t Report
18.00 hours
Candida h
 | + 59
- Pr | CITa
CITa | - 60
3, 2023 2:3
Patient I
Isolate
 | GRTas (+)
2:12 PM AST
D: EWGTEV
Physician:
Number: 1
Collected: | 54 IGLTa + 61 IPPOA + bioMfriex Customer + Jacket Name Quantity Leastin Lab ID 20 Paganism Customer + Commersite: Commersite: - Identification Information Selected Organism To Analysis
 | s55 62 1 | dXYLa +
2KGa +
F
 | 56 L 63 N Mic Analysis 93% Pro | ATa -
AGa +
robiology /
Time:
bability | S8 AC
64 dG
Chart Rep
18-20
Ca | Ea +
NTa +
ort
hours |) 52 59 Frinte | dGATa
CITa
d February | + 60
(3, 2023 2
Patient
Isolat | ESC
GRT
:30:42
t ID: E
Pl
le Num
 |
| 54 SGLT_0 4. 55 51 IPAnis No. 62 bioMétricex Customer: 62 bioMétricex Lacation: Lacation: Lacation: Lacation: Lacation: delto:4 Augustim : Candida Constraintin: Soloceted Organism Schered Organism T Databasis Messages Histehemiatal Detala 3 Lya 4
 | dXYLa
2KGa
Lusitaniae
 | - 56
- 63 | LATa
NAGa
Microbiol
nalysis Time:
% Probability
ionumber:
LeuA + | + 58
- 64
logy Charl | ACEa
dGNTa
t Report
18.00 hours
Candida h
70943565700
ARG +
 | + 59
- Pr
usitaniae
10 | CITa
inited February
Status:
ERYa - | - 60
3, 2023 2:3
Patient I
Isolate
Final
 | CRTax (+)
2:12 PM AST
D: WGTEV
Physician
Collected:
VLa - | 54 IGLTa + 61 IPROA + bioMfriersex Customer + + Patient Name: Variation + + Lab ID: 20 Pagasinen Quantify: + Selected Organism: - - Identification Informa Selected Organism -
 | s55 62 1 | dXYLa +
2KGa +
F
 | 56 L 63 N Mic Analysis 93% Pro | ATa +
AGa +
robiology
Time:
bability
eer: | S8 AC
64 dG
Chart Rep
18-20
Ca | Ea +
NTa +
ort
hours
ndida glab
006532700 |) 52 59 Frinte | dGATa
CITa
d February
Status: | + 60
r 3, 2023 2
Patient
Isolat | ESC
GRT
:30:42
t ID: E
Pl
le Num
 |
| 54 SCLT 4. 55 51 DPAO 2. 62 bioMericax Customer: Scherner 52 Jac ID-6 Appaintin Quartity: 52 genation Quartity: cleaters 52 Commontin: 52 Mannification Information Schered Organism Schered Organism Schered Organism ED Analysis Messages Bischermistal Detable
 | dXYLa
2KGa
 | - 56
- 63 | LATa
NAGa
Microbiol-
nalysis Time:
1% Probability
ionumber: | + 58
- 64
logy Charl | ACEa
dGNTa
t Report
18.00 hours
Candida h
70943565700
 | + 59
- Pr
usitaniae
00067
10
19 | CITa
CITa
Status: | - 60
3, 2023 2:3
Patient I
Isolate
 | CRTan (*) 2:12 PM AST 2:12 PM AST D: EWGTEV Physician Collected: | 54 IGLTa + 61 IPROA + bioMfriesex Customer + + Patient Name: Var - + Idad D2 20 Paganian Cast + Conneerin: - - + Keestification Information Selected Organism Cast + D Analysis Messages Biochemical Detable - + 3 LyaA - - -
 | | dXYLa +
2KGa +
F
ata
 | 56 L 63 N Mic Analysis 93% Pro Bionuml | AGa +
AGa +
Trobiology +
bability
eer: | 58 AC
64 dG
Chart Rep
18.20
Ca
60046 | Ea +
NTa +
ort
hours
ndida glab
06532700 |) 52 0
59 0
Printe | GGATa
CITTa
I d February
Status: | + 60
73, 2023 2
Patient
Isolat
Fin
12 6
20 G | aal
 |
| 54 SOLTA 4- 555 54 Modeline Contamere 62 Description Contamere Solution Contamere Solution Contamere Commentia: Las ID-4 Sognation Quarkins Conductor Solution Contamere Solution Contamere Solution Contamere Commentia: Image: Solution Information Solution Information Solution Contamere Image: Solution Information Solution Information Solution Information Solution Information Solution Solution Information Solution Solution Solution Information Solution Solution Solution Solution
 | IMLTa
BINAG
LACa
 | - 566
- 63 | LATa
NAGa
Microbiol
Nicrobiol
Probability
onumber: | + 58
- 64
logy Chart | ACEa
dGNTa
t Report
(8.00 hours
Candida l:
70943565700
ARG +
AMYa +
 | + 59
- Pr
unitaniae
10
19
27
34 | CITa
inited February
Status:
ERYa -
dGALa + | - 60
3, 2023 2:3
Patient I
Isolate
 | CRTas (+) 212 PM AST Provision: Provision: Number: 1 Collected: VLa - Na - ALa - ALa - | 54 IGLTs + 61 IPROM + bioMerican Cautioners + + Patient Name: V47 Laction So + Patient Name: V47 Laction So + Paranion Quantity: reserve: - Comments: - - Detected Organism ID Analysis Messages Bischemical Details 3 Type A 31 Type A - 21 AGLUL + 24 ARAFN -
 | 55 i 62 i adda glaber i s i s i | 4XYLa +
2XGa +
mta
LTa -
LTa -
LTa -
LTa -
LTa -
Ca -
Ca -
Ca -
Ca -
 | 56 L 63 N Mic 93% Pro Bionuml 5 LeuA 15 ARB 24 MAA 32 dMN | AGa +
AGa +
robiology
Time:
bability
ser:
a + 1
a - 1
a | 58 AC 64 dG Chart Rep 18.20 Ca 60046 7 ARG 18 ACH 18 ACH 60046 ACH 33 MMEL | bours bours bours bours bours bours |) 52 4
59 4
Printe | GGATa
CTTa
d February
Status:
YYa -
T -
LZa - | + 60
3,2023 2
Patient
Isolat
Fin
22 G
28 d
38 IS | ESC
GRT
30:42
ID: E
P
P
to Num
C
C |
| 14 S(2) 3 5 3 10 UPRO.s c 6 3 <t< td=""><td>dXYLa
2KGa
kusitanise
kusitanise
BNAG
LACa
NAGA1
XLTa
dTREa</td><td>- 566
- 63
- 63
- 63
- 63
- 63
- 63
- 63
-</td><td>LATa
NAGa
Microbiol
Microbiol
Probability
ionumber:</td><td>+ 58
- 64
- 64
- 54
- 18
- 18
- 18
- 26
- 33
- 44
- 51
- 51</td><td>ACEa
dGNTa
t Report
t Report
Candida la
70943565700
ARG +
AMYa +
dCELa -
SACa +
ARAA +</td><td>+ 59
- Pr
- Pr
- Pr
- Pr
- Pr
- Pr
- Pr
</td><td>CTTa
inited February
Status:
ERY/a -
GGT (-)
JMLZa +
URE -
URE -
4GATa +</td><td>- 60
3, 2023 2:3
Patient I
isolate
20 GE
28 MM
38 SB
38 SB
38 SB
33 ESS</td><td>GRTas (+) 2:12 PM AST (+) Display (+) Display (+) Collected: (+) VI.a (+) Na (+) Ea (+) Ea (+) LU (+)</td><td>54 IGLTs + 61 IPROA + bioMerican Cautioners + + biomerican - + Commerite: - - Commerite: - - Biochemical Details - - 3 LyaA - 21 - - - 22 - - - 23 BUAA - - 24 - - -</td><td>55 62 1 62 2 2 2 Indida glabri Indin glabri</td><td>4XYLa +
2KGa +
uts</td><td>56 L 63 N Analysis Mic 33% Pomber Bionuml Bionuml 5 Leave 15 ARBL 22 dMic 24 Model 44 No3</td><td>Image: Arrow of the second s</td><td>58 AC 64 dG 64 dG 7 ARG 7 ARG 7 ARG 18 AMY 26 ACEL 31 MEL 31 JAEL 31 JAEL 31 JAEL</td><td>hours
hours
holds glabal glaba</td><td>) 52 4
59 5
Printe</td><td>GGATa
CTTa
id February
Status:
Ya -
T -
T -
LZa -
T -
LZa -
T -
E -
ATa -</td><td>+ 60
3, 2023 2
Patient
Isolat
Fitt
220 G
28 df
38 l2
28 df
46 A
53 E</td><td>ESC
GRT
GRT
ID: E
P
P
P
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C</td></t<>
 | dXYLa
2KGa
kusitanise
kusitanise
BNAG
LACa
NAGA1
XLTa
dTREa | - 566
- 63
- 63
- 63
- 63
- 63
- 63
- 63
- | LATa
NAGa
Microbiol
Microbiol
Probability
ionumber:
 | + 58
- 64
- 64
- 54
- 18
- 18
- 18
- 26
- 33
- 44
- 51
- 51 | ACEa
dGNTa
t Report
t Report
Candida la
70943565700
ARG +
AMYa +
dCELa -
SACa +
ARAA + | + 59
- Pr
- Pr
- Pr
- Pr
- Pr
- Pr
- Pr
 | CTTa
inited February
Status:
ERY/a -
GGT (-)
JMLZa +
URE -
URE -
4GATa +
 | - 60
3, 2023 2:3
Patient I
isolate
20 GE
28 MM
38 SB
38 SB
38 SB
33 ESS
 | GRTas (+) 2:12 PM AST (+) Display (+) Display (+) Collected: (+) VI.a (+) Na (+) Ea (+) Ea (+) LU (+) | 54 IGLTs + 61 IPROA + bioMerican Cautioners + + biomerican - + Commerite: - - Commerite: - - Biochemical Details - - 3 LyaA - 21 - - - 22 - - - 23 BUAA - - 24 - - -
 | 55 62 1 62 2 2 2 Indida glabri Indin glabri | 4XYLa +
2KGa +
uts | 56 L 63 N Analysis Mic 33% Pomber Bionuml Bionuml 5 Leave 15 ARBL 22 dMic 24 Model 44 No3 | Image: Arrow of the second s | 58 AC 64 dG 64 dG 7 ARG 7 ARG 7 ARG 18 AMY 26 ACEL 31 MEL 31 JAEL 31 JAEL 31 JAEL | hours
hours
holds glabal glaba |) 52 4
59 5
Printe | GGATa
CTTa
id February
Status:
Ya -
T -
T -
LZa -
T -
LZa -
T -
E -
ATa - | + 60
3, 2023 2
Patient
Isolat
Fitt
220 G
28 df
38 l2
28 df
46 A
53 E | ESC
GRT
GRT
ID: E
P
P
P
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
 |
| 54 SGLT0 4. 55 Ball Broken 62 62 bioMereox Customer: 62 62 Patient Name: B Location 16 16 Symmin Quarks Examines 16 16 Symmin Quarks Examines 16 16 Comments: Examples 16 16 16 Comments: E 16 17 17 16 16 17 17 16 16 16 16 16 16 16 16 16
 | dXYLa
2KGa
dxyLa
2KGa
dxsitaniae
 | - 56
- 63
- 63
- 63
- 64
- 63
- 63
- 64
- 64
- 64
- 64
- 64
- 64
- 64
- 64 | LATa
NAGa
Microbiol
Probability
onumber: | + 58
- 64
- 64
- 164
- 164 | ACEa
dGNTa
t Report
18.00 hours
Candida la
70943565700
ARG +
AMYa +
dCELa -
SACa + | + 59
- Pr
- Pr
- Pr
- Pr
- Pr
- Pr
- Pr

 | CITa
inited February
Status:
ERYa -
dGALa +
GGT (-)
dMLZa +
URE - | - 60
3.2023-2:32
Patient I
Isolate
 | GRTas (+) 2:12 PM AST (+) Display (+) Display (+) Collected: (+) VI.a (+) Na (+) Ea (+) Ea (+) LU (+) | 54 IGLTs + 61 IPROs + bioMcinex Customers + - Jatien Name: V47 Location: - Landback Quantity: - - - convert - - - - Comments: - </td <td>55 62 1 62 2 2 2 Indida glabri Indin glabri</td> <td>4XYLa +
2KGa +
F
uta
LTa -
AG -
GA -
GA -
GA -
GA -
Ca -
GA -
Ca -
REa +</td> <td>56 L 63 N Analysis Wite 93% Provide Bionumb Bionumb 5 Leave 15 ARRE 42 MAN 42 dMA</td> <td>Xīa - AGa + robiologu + Time: - bability - train - 1 - Ga - La - a - a - a - a - a - a - a - a - a - a - a - a - a - a - a -</td> <td>58 AC 64 dG Chart Rep 18.20 Carton 60046 7 ARG 18 40 ARG 33 44 SAC</td> <td>Ea +
NTa +
ort -
nort -
no</td> <td>) 52 4
59 5
Frinte</td> <td>GGATa
CTTa
id February
Status:
Ya -
T -
T -
LZa -
T -
LZa -
T -
E -
ATa -</td> <td>+ 60
3, 2023 2: 2
Patient
Isolat
Fin</td> <td>ESC
GRI
30:42
ID: E
P
to Nun
C
C
aal</td>
 | 55 62 1 62 2 2 2 Indida glabri Indin glabri | 4XYLa +
2KGa +
F
uta
LTa -
AG -
GA -
GA -
GA -
GA -
Ca -
GA -
Ca -
REa + | 56 L 63 N Analysis Wite 93% Provide Bionumb Bionumb 5 Leave 15 ARRE 42 MAN 42 dMA | Xīa - AGa + robiologu + Time: - bability - train - 1 - Ga - La - a - a - a - a - a - a - a - a - a - a - a - a - a - a - a - | 58 AC 64 dG Chart Rep 18.20 Carton 60046 7 ARG 18 40 ARG 33 44 SAC | Ea +
NTa +
ort -
nort -
no |) 52 4
59 5
Frinte | GGATa
CTTa
id February
Status:
Ya -
T -
T -
LZa
-
T -
LZa -
T -
E -
ATa - | + 60
3, 2023 2: 2
Patient
Isolat
Fin | ESC
GRI
30:42
ID: E
P
to Nun
C
C
aal |
| 54 SCLT0 4- 55 541 WEICOL 4- 55 543 Mericol Consomer: 62 544 Mericol Consomer: 56 547 Selected Organism: Late ID-4 Selected Organism: 548 Selected Organism: E E 549 Selected Organism: E E 540 Menneths: E E 10 Analysis Messages E E 110 Analysis Messages 2 dBAH7 4 21 dGLUs 2 2 dBAH7 2 20 dBAH7 2 4 2 2 20 dBAH7 4 <td< td=""><td>MACAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MAR</td><td>- 566
- 63
- 63
- 63
- 63
- 63
- 63
- 63
-</td><td>LATa NAGa Microbiol Microb</td><td>+ 58
- 64
ogy Chart
- 18
- 18
- 18
- 18
- 18
- 18
- 18
- 19
- 19
- 19
- 19
- 19
- 19
- 19
- 19</td><td>ACEa
dGNTa
t Report
Candida Ide
ARG + 1
405455700
ARG + 1
405424
ARG + 1
405444
ARG + 1
40544
ARG + 1
405444
ARG + 1
405444
ARG + 1
405444
ARG + 1
4054444
ARG + 1
4054444
ARG + 1
4054444
ARG + 1
4054444
ARG + 1
4054444
ARG + 1
40544444
ARG + 1
40544444444444444444444444444444444444</td><td>+ 59
- Pr
- Pr
- Pr
- Pr
- Pr
- Pr
- Pr
</td><td>CTTa
inited February
Status:
ERY/a -
GGT (-)
JMLZa +
URE -
URE -
4GATa +</td><td>60
3, 2023 2:3
Patient It
Isolate
12
20 6L
28 4BM
46 46 46
46 46 46
46 46 46
46 46 46
46 46 46 46 46 46
46 46 46 46 46
46 46 46 46 46 46 46 46 46 46 46 46 46 4</td><td>GRTen +) D.12 PM AST D.15 KGTN D.15 KGTN Provision Provision - Collected: - VI.a - K1 - L0 - Tra -</td><td>54 102.Ta + 101 1990.0 + bioMerican Cautioners + - bioMerican Cautioners + - Partien Neuroners + - Commerste - - Commerste - - Hoterification Informa Selected Organism - 10 Analysis Messaget - 20 402.47 - 21 402.47 - 22 402.47 - 23 402.44 - 24 402.48 - 54 102.75 - 54 102.75 - 54 102.75 - 54 102.75 - 54 102.75 - 54 102.75 -</td><td>55 62 62 2 andida glaber 1 4 IMI 3 IMI 44 M 45 IMI 62 2</td><td>4XYLa + 4
XXGa + 4
T
T
ata
LTa - 4
CAG - 4</td><td>56 L 63 N Mic Mic 935% Proto Bionuml Bionuml 5 Leau 15 ARII 24 MAC 42 dSOI 42 dSOI 43 NO3 56
LATR</td><td>Time:
Time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
tim</td><td>58 AC 64 #G 64 #G Chart Rep 18.20 Ca 60046 7 ARG 8 ACEa 91 ARA 92 ARCEA 93 ARCEA 94 ACNT</td><td>Ea +
NTa +
oort
hours
a -
a -
a -
a -
a -
a -
a -
a</td><td>) 52 4
59 5
Printe</td><td>GGATa
CTTa
id February
Status:
Ya -
T -
T -
LZa -
T -
LZa -
T -
E -
ATa -</td><td>+ 60
3, 2023 2
Patient
Isolat
Fitt
220 G
28 df
38 l2
28 df
46 A
53 E</td><td>ESC
GRT
GRT
ID: E
P
P
P
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C</td></td<> | MACAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MAR | - 566
- 63
- 63
- 63
- 63
- 63
- 63
- 63
- | LATa NAGa Microbiol Microb | + 58
- 64
ogy Chart
- 18
- 18
- 18
- 18
- 18
- 18
- 18
- 19
- 19
- 19
- 19
- 19
- 19
- 19
- 19
 | ACEa
dGNTa
t Report
Candida Ide
ARG + 1
405455700
ARG + 1
405424
ARG + 1
405444
ARG + 1
40544
ARG + 1
405444
ARG + 1
405444
ARG + 1
405444
ARG + 1
4054444
ARG + 1
4054444
ARG + 1
4054444
ARG + 1
4054444
ARG + 1
4054444
ARG + 1
40544444
ARG + 1
40544444444444444444444444444444444444 | + 59
- Pr
- Pr
- Pr
- Pr
- Pr
- Pr
- Pr
 | CTTa
inited February
Status:
ERY/a -
GGT (-)
JMLZa +
URE -
URE -
4GATa + | 60
3, 2023 2:3
Patient It
Isolate
12
20 6L
28 4BM
46 46 46
46 46 46
46 46 46
46 46 46
46 46 46 46 46 46
46 46 46 46 46
46 46 46 46 46 46 46 46 46 46 46 46 46 4
 | GRTen +) D.12 PM AST D.15 KGTN D.15 KGTN Provision Provision - Collected: - VI.a - K1 - L0 - Tra - | 54 102.Ta + 101 1990.0 + bioMerican Cautioners + - bioMerican Cautioners + - Partien Neuroners + - Commerste - - Commerste - - Hoterification Informa Selected Organism - 10 Analysis Messaget - 20 402.47 - 21 402.47 - 22 402.47 - 23 402.44 - 24 402.48 - 54 102.75 - 54 102.75 - 54 102.75 - 54 102.75 - 54 102.75 - 54 102.75 -
 | 55 62 62 2 andida glaber 1 4 IMI 3 IMI 44 M 45 IMI 62 2 | 4XYLa + 4
XXGa + 4
T
T
ata
LTa - 4
CAG - 4 | 56 L 63 N Mic Mic 935% Proto Bionuml Bionuml 5 Leau 15 ARII 24 MAC 42 dSOI 42 dSOI 43 NO3 56 LATR |
Time:
Time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
time:
tim | 58 AC 64 #G 64 #G Chart Rep 18.20 Ca 60046 7 ARG 8 ACEa 91 ARA 92 ARCEA 93 ARCEA 94 ACNT | Ea +
NTa +
oort
hours
a -
a -
a -
a -
a -
a -
a -
a |) 52 4
59 5
Printe | GGATa
CTTa
id February
Status:
Ya -
T -
T -
LZa -
T -
LZa -
T -
E -
ATa - | + 60
3, 2023 2
Patient
Isolat
Fitt
220 G
28 df
38 l2
28 df
46 A
53 E | ESC
GRT
GRT
ID: E
P
P
P
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C |
| 54 SCLT0 4- 55 541 WEICOL 4- 55 543 Mericol Consomer: 62 544 Mericol Consomer: 56 547 Selected Organism: Late ID-4 Selected Organism: 548 Selected Organism: E E 549 Selected Organism: E E 540 Menneths: E E 10 Analysis Messages E E 110 Analysis Messages 2 dBAH7 4 21 dGLUs 2 2 dBAH7 2 20 dBAH7 2 4 2 2 20 dBAH7 4 <td< td=""><td>MACAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MAR</td><td>- 566
- 63
- 63
- 63
- 63
- 63
- 63
- 63
-</td><td>LATs NAGS Microbiolo M</td><td>+ 58
- 64
- 64
- 64
- 7
- 18
- 26
- 18
- 26
- 18
- 26
- 33
- 58
- 58
- 58
- 58
- 58
- 58
- 58
- 58</td><td>ACEa
dGNTa
t Report
Candida Ide
ARG + 1
405455700
ARG + 1
405424
ARG + 1
405444
ARG + 1
40544
ARG + 1
405444
ARG + 1
405444
ARG + 1
405444
ARG + 1
4054444
ARG + 1
4054444
ARG + 1
4054444
ARG + 1
4054444
ARG + 1
4054444
ARG + 1
40544444
ARG + 1
40544444444444444444444444444444444444</td><td>+ 59
</td><td>CTTa
inited February
Status:
ERY/a -
GGT (-)
JMLZa +
URE -
URE -
4GATa +</td><td>60
3, 2023 2:3
Patient It
Isolate
12
20 6L
28 4BM
46 46 46
46 46 46
46 46 46
46 46 46
46 46 46 46
46 46 46 46 46 46 46 46 46 46 46 46 46 4</td><td>GRTen +) D.12 PM AST D.15 KGTN D.15 KGTN Provision Provision - Collected: - VI.a - K1 - L0 - Tra -</td><td>54 IGLT:n + 61 IPROs + bioMcinex Customer:
Langen + + Location:
Langen + + Location:
Langen + + Comments: - + Comments: - + Biochemical Organim: 10 Analysis Menagee Biochemical Details 3 13 Type (-) 20 dRAFa + 29 RRAFa + 47 dGLLa + 42 47URa + 43 IPROa +</td><td>55 62 62 2 andida glaber 1 4 IMI 3 IMI 44 M 45 IMI 62 2</td><td>4XYLa +
2KGa +
F
uta
LTa -
AG -
GA -
GA -
GA -
GA -
Ca -
GA -
Ca -
REa +</td><td>56 L 63 N Mic Mic 935% Proto Bionuml Bionuml 5 Leau 15 ARII 24 MAC 42 dSOI 42 dSOI 43 NO3 56 LATR</td><td>Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Ti</td><td>58 AC 64 dG 64 dG 7 ARG 7 ARG 8 ACC 33 MMEL 33 AMEL 58 ACEL
 58 ACEL 59 ACEL 60046 ACEL 7 ARG 7 ARG 8 AVY 8 ACEL 4 AAM D: HV S ACEL</td><td>Ea +
NTa +
ort -
-
-
-
-
-
-
-
-
-</td><td>) 52 4
59 5
Printe</td><td>GGATa
CTTa
id February
Status:
Ya -
T -
T -
LZa -
T -
LZa -
T -
E -
ATa -</td><td>+ 60
3, 2023 2
Patient
Isolat
Fitt
220 G
28 df
38 l2
28 df
46 A
53 E</td><td>ESC
GRT
GRT
C
GRT
P
P
P
P
P
P
P
P
P
P
P
P
P
P
P
P
P
P
P</td></td<> | MACAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MAR | - 566
- 63
- 63
- 63
- 63
- 63
- 63
- 63
- | LATs NAGS Microbiolo M | + 58
- 64
- 64
- 64
- 7
- 18
- 26
- 18
- 26
- 18
- 26
- 33
- 58
- 58
- 58
- 58
- 58
- 58
- 58
- 58
 | ACEa
dGNTa
t Report
Candida Ide
ARG + 1
405455700
ARG + 1
405424
ARG + 1
405444
ARG + 1
40544
ARG + 1
405444
ARG + 1
405444
ARG + 1
405444
ARG + 1
4054444
ARG + 1
4054444
ARG + 1
4054444
ARG + 1
4054444
ARG + 1
4054444
ARG + 1
40544444
ARG + 1
40544444444444444444444444444444444444 | + 59
 | CTTa
inited February
Status:
ERY/a -
GGT (-)
JMLZa +
URE -
URE -
4GATa + | 60
3, 2023 2:3
Patient It
Isolate
12
20 6L
28 4BM
46 46 46
46 46 46
46 46 46
46 46 46
46 46 46 46
46 46 46 46 46 46 46 46 46 46 46 46 46 4
 | GRTen +) D.12 PM AST D.15 KGTN D.15 KGTN Provision Provision - Collected: - VI.a - K1 - L0 - Tra -
 | 54 IGLT:n + 61 IPROs + bioMcinex Customer:
Langen + + Location:
Langen + + Location:
Langen + + Comments: - + Comments: - + Biochemical Organim: 10 Analysis Menagee Biochemical Details 3 13 Type (-) 20 dRAFa + 29 RRAFa + 47 dGLLa + 42 47URa + 43 IPROa +
 | 55 62 62 2 andida glaber 1 4 IMI 3 IMI 44 M 45 IMI 62 2 | 4XYLa +
2KGa +
F
uta
LTa -
AG -
GA -
GA -
GA -
GA -
Ca -
GA -
Ca -
REa + | 56 L 63 N Mic Mic 935% Proto Bionuml Bionuml 5 Leau 15 ARII 24 MAC 42 dSOI 42 dSOI 43 NO3 56 LATR | Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Time:
Ti | 58 AC 64 dG 64 dG 7 ARG 7 ARG 8 ACC 33 MMEL 33 AMEL 58 ACEL 58 ACEL 59 ACEL 60046 ACEL 7 ARG 7 ARG 8 AVY 8 ACEL 4 AAM D: HV S ACEL | Ea +
NTa +
ort -
-
-
-
-
-
-
-
-
-
 |) 52 4
59 5
Printe | GGATa
CTTa
id February
Status:
Ya -
T -
T -
LZa -
T -
LZa -
T -
E -
ATa - | + 60
3, 2023 2
Patient
Isolat
Fitt
220 G
28 df
38 l2
28 df
46 A
53 E | ESC
GRT
GRT
C
GRT
P
P
P
P
P
P
P
P
P
P
P
P
P
P
P
P
P
P
P |
| 54 SCLT0 4- 55 541 WEICOL 4- 55 543 Mericol Consomer: 62 544 Mericol Consomer: 56 547 Selected Organism: Late ID-4 Selected Organism: 548 Selected Organism: E E 549 Selected Organism: E E 540 Menneths: E E 10 Analysis Messages E E 110 Analysis Messages 2 dBAH7 4 21 dGLUs 2 2 dBAH7 2 20 dBAH7 2 4 2 2 20 dBAH7 4 <td< td=""><td>MACAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MAR</td><td>- 566
- 63
- 63
- 63
- 63
- 63
- 63
- 63
-</td><td>LATs
NAGa
Microbiolo
Microbiolo
Microbiolo
Strobalistic
Strobalistic
Madias
MAGa
MAGa
MAGa
MAGa
MAGa
MAGa
MAGa
MAGa</td><td>+ 58
- 64
- 64
- 64
- 64
- 18
- 26
- 18
- 26
- 18
- 26
- 33
- 34
- 51
- 1
- 58
</td><td>ACEa
dGNTa
Report
Candida Ii
MIPLA
MANYa
MANYa
MANYa
MANYa
MANYa
MANYa
MANYA
MANYA
MANYA
MANYA
MANYA
MANYA
MANA
MAN</td><td>+ 59
</td><td>CTTa
inited February
Status:
BERYs -
dGALa +
GGT (-)
dGALa +
URE -
URE -
dGATa +
CTTa +
CTTa +
CTTa -</td><td>60
3, 2023 2:3
Patient It
Isolate
12
20 6L
28 4BM
46 46 46
46 46 46
46 46 46
46 46 46
46 46 46 46
46 46 46 46 46 46 46 46 46 46 46 46 46 4</td><td>GRTen +) D.12 PM AST D.15 KGTN D.15 KGTN Provision Provision - Collected: - VI.a - K1 - L0 - Tra -</td><td>54 102.Ta + 101 1990.0 + bioMerican Cautioners + - bioMerican Cautioners + - Partien Neuroners + - Commerste - - Commerste - - Hoterification Informa Selected Organism - 10 Analysis Messaget - 20 402.47 - 21 402.47 - 22 402.47 - 23 402.44 - 24 402.48 - 54 102.75 - 54 102.75 - 54 102.75 - 54 102.75 - 54 102.75 - 54 102.75 -</td><td>55 62 62 2 andida glaber 1 4 IMI 3 IMI 44 M 45 IMI 62 2</td><td>4XYLa + 4
XXGa + 4
T
T
ata
LTa - 4
CAG - 4</td><td>56 L 63 N Mic Mic 935% Proto Bionuml Bionuml 5 Leau 15 ARII 24 MAC 42 dSOI 42 dSOI 43 NO3 56 LATR</td><td>Time:
Time:
Time:
bability
er:</td><td>58 AC 64 #GG 18.20 Ca 7 ARG 78 AMY2 70 Ca 70 Ca 71 ARG 72 Ca 73 ARG 74 AMY2</td><td>Ea + + + + + + + + + + + + + + + + + + +</td><td>) 52 4
59 5
Printe</td><td>GGATa
CTTa
id February
Status:
Ya -
T -
T -
LZa -
T -
LZa -
T -
E -
ATa -</td><td>+ 60
3, 2023 2
Patient
Isolat
Fitt
220 G
28 df
38 l2
28 df
46 A
53 E</td><td>ESC
GRT
GRT
ID: E
P
P
P
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C</td></td<>
 | MACAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MAR | - 566
- 63
- 63
- 63
- 63
- 63
- 63
- 63
- | LATs
NAGa
Microbiolo
Microbiolo
Microbiolo
Strobalistic
Strobalistic
Madias
MAGa
MAGa
MAGa
MAGa
MAGa
MAGa
MAGa
MAGa
 | + 58
- 64
- 64
- 64
- 64
- 18
- 26
- 18
- 26
- 18
- 26
- 33
- 34
- 51
- 1
- 58
 | ACEa
dGNTa
Report
Candida Ii
MIPLA
MANYa
MANYa
MANYa
MANYa
MANYa
MANYa
MANYA
MANYA
MANYA
MANYA
MANYA
MANYA
MANA
MAN | + 59

 | CTTa
inited February
Status:
BERYs -
dGALa +
GGT (-)
dGALa +
URE -
URE -
dGATa +
CTTa +
CTTa +
CTTa - | 60
3, 2023 2:3
Patient It
Isolate
12
20 6L
28 4BM
46 46 46
46 46 46
46 46 46
46 46 46
46 46 46 46
46 46 46 46 46 46 46 46 46 46 46 46 46 4
 | GRTen +) D.12 PM AST D.15 KGTN D.15 KGTN Provision Provision - Collected: - VI.a - K1 - L0 - Tra - | 54 102.Ta + 101 1990.0 + bioMerican Cautioners + - bioMerican Cautioners + - Partien Neuroners + - Commerste - - Commerste - - Hoterification Informa Selected Organism - 10 Analysis Messaget - 20 402.47 - 21 402.47 - 22 402.47 - 23 402.44 - 24 402.48 - 54 102.75 - 54 102.75 - 54 102.75 - 54 102.75 - 54 102.75 - 54 102.75 -
 | 55 62 62 2 andida glaber 1 4 IMI 3 IMI 44 M 45 IMI 62 2 | 4XYLa + 4
XXGa + 4
T
T
ata
LTa - 4
CAG - 4 | 56 L 63 N Mic Mic 935% Proto Bionuml Bionuml 5 Leau 15 ARII 24 MAC 42 dSOI 42 dSOI 43 NO3 56 LATR | Time:
Time:
Time:
bability
er: | 58 AC 64 #GG 18.20 Ca 7 ARG 78 AMY2 70 Ca 70 Ca 71
 ARG 72 Ca 73 ARG 74 AMY2 | Ea + + + + + + + + + + + + + + + + + + + |) 52 4
59 5
Printe | GGATa
CTTa
id February
Status:
Ya -
T -
T -
LZa -
T -
LZa -
T -
E -
ATa - | + 60
3, 2023 2
Patient
Isolat
Fitt
220 G
28 df
38 l2
28 df
46 A
53 E | ESC
GRT
GRT
ID: E
P
P
P
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C |
| 54 SCLT0 4- 55 541 WEICOL 4- 55 543 Mericol Consomer: 62 544 Mericol Consomer: 56 547 Selected Organism: Late ID-4 Selected Organism: 548 Selected Organism: E E 549 Selected Organism: E E 540 Menneths: E E 10 Analysis Messages E E 110 Analysis Messages 2 dBAH7 4 21 dGLUs 2 2 dBAH7 2 20 dBAH7 2 4 2 2 20 dBAH7 4 <td< td=""><td>MACAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MAR</td><td>- 566
- 63
- 63
- 63
- 63
- 63
- 63
- 63
-</td><td>L/Ts NAGa Microbiol Microb</td><td>+ 58
- 64
- 64
- 7
- 18
- 1
- 18
- 1
- 18
- 1
- 18
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1</td><td>ACEa
dGNTa
Report
Candida Ii
MIPLA
MANYa
MANYa
MANYa
MANYa
MANYa
MANYa
MANYA
MANYA
MANYA
MANYA
MANYA
MANYA
MANA
MAN</td><td>+ 59
</td><td>CTTa initial February IStatus: IRYA AGAINA AGAINA INITIAL AGAINA I</td><td>60
3, 2023 2:3
Patient It
Isolate
12
20 6L
28 4BM
46 46 46
46 46 46
46 46 46
46 46 46
46 46 46 46
46 46 46 46 46 46 46 46 46 46 46 46 46 4</td><td>GRTen +) D.12 PM AST D.15 KGTN D.15 KGTN Provision Provision - Collected: - VI.a - K1 - L0 - Tra -</td><td>54 102.Ta + 101 1990.0 + bioMerican Cautioners + - bioMerican Cautioners + - Partien Neuroners + - Commerste - - Commerste - - Hoterification Informa Selected Organism - 10 Analysis Messaget - 20 402.47 - 21 402.47 - 22 402.47 - 23 402.44 - 24 402.48 - 54 102.75 - 54 102.75 - 54 102.75 - 54 102.75 - 54 102.75 - 54 102.75 -</td><td>55 62 62 2 andida glaber 1 4 IMI 3 IMI 44 M 45 IMI 62 2</td><td>4XYLa + 4
XXGa + 4
T
T
ata
LTa - 4
CAG - 4</td><td>56 L 63 N Mic Mic 935% Proto Bionuml Bionuml 5 Leau 15 ARII 24 MAC 42 dSOI 42 dSOI 43 NO3 56 LATR</td><td>Time:
Time:
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tababil</td><td>58 ACC 64 dG 18.20 Chart Rep 18.20 Cc 60046 Co 7 ARG (60046 7 ARG (31) 88 ACE (31) 96 GELES (31) 98 ACE (34) 98 ACE (34) 91 JARA (34) 92 JARA (34) 94 ACH (12) 94 ACH (12) 97 Physici.</td><td>Ea + + + + + + + + + + + + + + + + + + +</td><td>) 52 4
59 5
Printe</td><td>GGATa
CTTa
id
February
Status:
Ya -
T -
T -
LZa -
T -
LZa -
T -
E -
ATa -</td><td>+ 60
3, 2023 2
Patient
Isolat
Fitt
220 G
28 df
38 l2
28 df
46 A
53 E</td><td>ESC
GRT
GRT
C
GRT
P
P
P
P
P
P
P
P
P
P
P
P
P
P
P
P
P
P
P</td></td<> | MACAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MAR | - 566
- 63
- 63
- 63
- 63
- 63
- 63
- 63
- | L/Ts NAGa Microbiol Microb | + 58
- 64
- 64
- 7
- 18
- 1
- 18
- 1
- 18
- 1
- 18
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1 | ACEa
dGNTa
Report
Candida Ii
MIPLA
MANYa
MANYa
MANYa
MANYa
MANYa
MANYa
MANYA
MANYA
MANYA
MANYA
MANYA
MANYA
MANA
MAN
 | + 59
 | CTTa initial February IStatus: IRYA AGAINA AGAINA INITIAL AGAINA I | 60
3, 2023 2:3
Patient It
Isolate
12
20 6L
28 4BM
46 46 46
46 46 46
46 46 46
46 46 46
46 46 46 46
46 46 46 46 46 46 46 46 46 46 46 46 46 4
 | GRTen +) D.12 PM AST D.15 KGTN D.15 KGTN Provision Provision - Collected: - VI.a - K1 - L0 - Tra - | 54 102.Ta + 101 1990.0 + bioMerican Cautioners + - bioMerican Cautioners + - Partien Neuroners + - Commerste - - Commerste - - Hoterification Informa Selected Organism - 10 Analysis Messaget - 20 402.47 - 21 402.47 - 22 402.47 - 23 402.44 - 24 402.48 - 54 102.75 - 54 102.75 - 54 102.75 - 54 102.75 - 54 102.75 - 54 102.75 -
 | 55 62 62 2 andida glaber 1 4 IMI 3 IMI 44 M 45 IMI 62 2 | 4XYLa + 4
XXGa + 4
T
T
ata
LTa - 4
CAG - 4 | 56 L 63 N Mic Mic 935% Proto Bionuml Bionuml 5 Leau 15 ARII 24 MAC 42 dSOI 42 dSOI 43 NO3 56 LATR |
Time:
Time:
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tababil | 58 ACC 64 dG 18.20 Chart Rep 18.20 Cc 60046 Co 7 ARG (60046 7 ARG (31) 88 ACE (31) 96 GELES (31) 98 ACE (34) 98 ACE (34) 91 JARA (34) 92 JARA (34) 94 ACH (12) 94 ACH (12) 97 Physici. | Ea + + + + + + + + + + + + + + + + + + + |) 52 4
59 5
Printe | GGATa
CTTa
id February
Status:
Ya -
T -
T -
LZa -
T -
LZa -
T -
E -
ATa - | + 60
3, 2023 2
Patient
Isolat
Fitt
220 G
28 df
38 l2
28 df
46 A
53 E | ESC
GRT
GRT
C
GRT
P
P
P
P
P
P
P
P
P
P
P
P
P
P
P
P
P
P
P |
| 54 SCLT0 4- 55 541 WEICOL 4- 55 543 Mericol Consomer: 62 544 Mericol Consomer: 56 547 Selected Organism: Late ID-4 Selected Organism: 548 Selected Organism: E E 549 Selected Organism: E E 540 Menneths: E E 10 Analysis Messages E E 110 Analysis Messages 2 dBAH7 4 21 dGLUs 2 2 dBAH7 2 20 dBAH7 2 4 2 2 20 dBAH7 4 <td< td=""><td>MACAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MAR</td><td>- 566
- 63
- 63
- 63
- 63
- 63
- 63
- 63
-</td><td>L/Ts NAGa Microbiol Microb</td><td>+ 58
- 64
- 64
- 7
- 18
- 7
- 18
- 7
- 18
- 3
- 44
- 51
- 33
- 44
- 51
- 58
- 58
- 58
- 58
- 58
- 58
- 58
- 64
- 64
- 64
- 64
- 64
- 64
- 64
- 64</td><td>ACEa dGNTa dGNTa dGNTa Report GReport Gadda Iso GReport Gadda Iso GReport ARG + I MARY + I MELa - I ACEa + I ARG + I MHEA - I ACEa + I HARA - I HARA - I HOTORY: - J Jub Jub Jub Jub Jub Jub Jub Jub Jub Jub</td><td>+ 59
</td><td>CTTa initial February IStatus: IRYA AGAINA AGAINA INITIAL AGAINA I</td><td>60
3, 2023 2:3
Patient It
Isolate
12
20 6L
28 4BM
46 46 46
46 46 46
46 46 46
46 46 46
46 46 46 46
46 46 46 46 46 46 46 46 46 46 46 46 46 4</td><td>GRTen +) D.12 PM AST D.15 KGTN D.15 KGTN Provision Provision - Collected: - VI.a - K1 - L0 - Tra -</td><td>54 102.Ta + 101 1990.0 + bioMerican Cautioners + - bioMerican Cautioners + - Partien Neuroners + - Commerste - - Commerste - - Hoterification Informa Selected Organism - 10 Analysis Messaget - 20 402.47 - 21 402.47 - 22 402.47 - 23 402.44 - 24 402.48 - 54 102.75 - 54 102.75 - 54 102.75 - 54 102.75 - 54 102.75 - 54 102.75 -</td><td>55 62 62 2 andida glaber 1 4 IMI 3 IMI 44 M 45 IMI 62 2</td><td>4XYLa + 4
XXGa + 4
T
T
ata
LTa - 4
CAG - 4</td><td>56 L 63 N Mic Mic 935% Proto Bionuml Bionuml 5 Leau 15 ARII 24 MAC 42 dSOI 42 dSOI 43 NO3 56 LATR</td><td>Time:
Time:
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tababil</td><td>58 ACC 64 dG 18.20 Chart Rep 18.20 Cc 60046 Co 7 ARG (60046 7 ARG (31) 88 ACE
(31) 96 GELES (31) 98 ACE (34) 98 ACE (34) 91 JARA (34) 92 JARA (34) 94 ACH (12) 94 ACH (12) 97 Physici.</td><td>Ea + + + + + + + + + + + + + + + + + + +</td><td>) 52 4
59 5
Printe</td><td>GGATa
CTTa
id February
Status:
Ya -
T -
T -
LZa -
T -
LZa -
T -
E -
ATa -</td><td>+ 60
3, 2023 2
Patient
Isolat
Fitt
220 G
28 df
38 l2
28 df
46 A
53 E</td><td>ESC
GRT
GRT
C
GRT
P
P
P
P
P
P
P
P
P
P
P
P
P
P
P
P
P
P
P</td></td<> | MACAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MAR | - 566
- 63
- 63
- 63
- 63
- 63
- 63
- 63
- | L/Ts NAGa Microbiol Microb | + 58
- 64
- 64
- 7
- 18
- 7
- 18
- 7
- 18
- 3
- 44
- 51
- 33
- 44
- 51
- 58
- 58
- 58
- 58
- 58
- 58
- 58
- 64
- 64
- 64
- 64
- 64
- 64
- 64
- 64 | ACEa dGNTa dGNTa dGNTa Report GReport Gadda Iso GReport Gadda Iso GReport ARG + I MARY + I MELa - I ACEa + I ARG + I MHEA - I ACEa +
I HARA - I HARA - I HOTORY: - J Jub | + 59
 | CTTa initial February IStatus: IRYA AGAINA AGAINA INITIAL AGAINA I | 60
3, 2023 2:3
Patient It
Isolate
12
20 6L
28 4BM
46 46 46
46 46 46
46 46 46
46 46 46
46 46 46 46
46 46 46 46 46 46 46 46 46 46 46 46 46 4
 | GRTen +) D.12 PM AST D.15 KGTN D.15 KGTN Provision Provision - Collected: - VI.a - K1 - L0 - Tra - | 54 102.Ta + 101 1990.0 + bioMerican Cautioners + - bioMerican Cautioners + - Partien Neuroners + - Commerste - - Commerste - - Hoterification Informa Selected Organism - 10 Analysis Messaget - 20 402.47 - 21 402.47 - 22 402.47 - 23 402.44 - 24 402.48 - 54 102.75 - 54 102.75 - 54 102.75 - 54 102.75 - 54 102.75 - 54 102.75 -
 | 55 62 62 2 andida glaber 1 4 IMI 3 IMI 44 M 45 IMI 62 2 | 4XYLa + 4
XXGa + 4
T
T
ata
LTa - 4
CAG - 4 | 56 L 63 N Mic Mic 935% Proto Bionuml Bionuml 5 Leau 15 ARII 24 MAC 42 dSOI 42 dSOI 43 NO3 56 LATR |
Time:
Time:
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tababil | 58 ACC 64 dG 18.20 Chart Rep 18.20 Cc 60046 Co 7 ARG (60046 7 ARG (31) 88 ACE (31) 96 GELES (31) 98 ACE (34) 98 ACE (34) 91 JARA (34) 92 JARA (34) 94 ACH (12) 94 ACH (12) 97 Physici. | Ea + + + + + + + + + + + + + + + + + + + |) 52 4
59 5
Printe | GGATa
CTTa
id February
Status:
Ya -
T -
T -
LZa -
T -
LZa -
T -
E -
ATa - | + 60
3, 2023 2
Patient
Isolat
Fitt
220 G
28 df
38 l2
28 df
46 A
53 E | ESC
GRT
GRT
C
GRT
P
P
P
P
P
P
P
P
P
P
P
P
P
P
P
P
P
P
P |
| 54 SCLT0 4- 55 541 WEICOL 4- 55 543 Mericol Consomer: 62 544 Mericol Consomer: 56 547 Selected Organism: Late ID-4 Selected Organism: 548 Selected Organism: E E 549 Selected Organism: E E 540 Mennetification Information: Selected Organism: E 10 Analysis Messages: E E E 110 Analysis Messages: 2 B B 2 3 13 3 3 3 3 9 B 4 2 3 3 9 8 4 2 3 3 9 9 8 4 3 2 9 9 8 4 4 3 1 4 4 4 4 4 4 4 4 4 4 4 4 4<
 |
MACAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MAR | - 566
- 63
- 63
- 63
- 63
- 63
- 63
- 63
- | Ld's
NAGa
Microbiol
microbiol
spinistrane
5% Probability
commber
5% Probability
commber
5% Probability
commber
5% Probability
down
4
MAGa
4
MAGa
4
MAGa
5%
5%
5%
5%
5%
5%
5%
5%
5%
5%
5%
5%
5% | + ss
64
ogy Chart
7
18
26
33
44
51
11
58
51
158
58
34
44
51
158
58
10
58
10
58
10
58
10
58
10
58
10
58
10
58
10
58
10
58
10
58
10
58
10
58
10
58
10
58
10
58
10
58
10
58
10
58
10
58
10
58
10
58
10
58
10
58
10
58
10
58
10
58
10
58
10
58
10
58
10
58
10
58
10
58
10
58
10
58
10
58
10
58
10
58
10
58
10
58
10
58
10
58
10
58
10
58
10
58
10
58
10
58
10
58
10
58
10
58
10
58
10
58
10
58
10
58
10
58
10
58
10
58
10
58
10
58
10
58
10
58
10
58
10
58
10
58
10
58
10
58
10
58
10
58
10
58
10
58
10
58
10
58
10
58
10
58
10
58
10
58
10
58
10
58
10
58
10
58
10
58
10
58
10
58
10
58
10
58
10
58
10
58
10
58
10
58
10
58
10
58
10
58
10
58
10
58
10
58
10
58
10
58
10
58
10
58
10
58
10
58
10
58
10
58
10
58
10
58
10
58
10
58
10
58
10
58
10
58
10
58
10
58
10
58
10
58
10
58
10
58
10
58
10
58
10
58
10
58
10
58
10
58
10
58
10
58
10
58
10
58
10
58
10
58
10
58
10
58
10
58
10
58
10
58
10
58
10
58
10
58
10
58
10
58
10
58
10
58
10
58
10
58
10
58
10
58
10
58
10
58
10
58
10
58
10
58
10
58
10
58
10
58
10
58
10
58
10
58
10
58
10
58
10
58
10
58
10
58
10
58
10
58
10
58
10
58
10
58
10
58
10
58
10
58
10
58
10
58
10
58
10
58
10
58
10
58
10
58
10
58
10
58
10
58
10
58
10
58
10
58
10
58
10
58
10
58
10
58
10
58
10
58
10
58
10
58
10
58
10
58
10
58
10
58
10
58
10
58
10
58
10
58
10
58
10
58
10
58
10
58
10
58
10
58
10
58
10
58
10
58
10
58
10
58
10
58
10
58
10
58
10
58
10
58
10
58
10
58
10
58
10
58
10
58
10
58
10
58
10
58
10
58
10
58
10
58
10
10
10
10
10
10
10
10
10
10
10
10
10 | ACEa dGNTa dGNTa dGNTa Report GReport Gadda Iso GReport Gadda Iso GReport ARG + I MARY + I MELa - I ACEa + I ARG + I MHEA - I ACEa + I HARA - I HARA - I HOTORY: - J Jub
 | + 59
 | CTTa initial February IStatus: IRYA AGAINA AGAINA INITIAL AGAINA I | 60
3, 2023 2:3
Patient It
Isolate
12
20 6L
28 4BM
46 46 46
46 46 46
46 46 46
46 46 46
46 46 46 46
46 46 46 46 46 46 46 46 46 46 46 46 46 4
 | GRTen +) D.12 PM AST D.15 KGTN D.15 KGTN Provision Provision - Collected: - VI.a - K1 - L0 - Tra - | 54 102.Ta + 101 1990.0 + bioMerican Cautioners + - bioMerican Cautioners + - Partien Neuroners + - Commerste - - Commerste - - Hoterification Informa Selected Organism - 10 Analysis Messaget - 20 402.47 - 21 402.47 - 22 402.47 - 23 402.44 - 24 402.48 - 54 102.75 - 54 102.75 - 54 102.75 - 54 102.75 - 54 102.75 - 54 102.75 -
 | 55 62 62 2 andida glaber 1 4 IMI 3 IMI 44 M 45 IMI 62 2 | 4XYLa + 4
XXGa + 4
T
T
ata
LTa - 4
CAG - 4 | 56 L 63 N Mic Mic 935% Proto Bionuml Bionuml 5 Leau 15 ARII 24 MAC 42 dSOI 42 dSOI 43 NO3 56 LATR |
Time:
Time:
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tababil | 58 AC 18.20 Chart Rep 19.30 State Rep 10.20 HVS 10.20 Physicicit Rep 10.20 Physicit Rep 10.20 Physicit Rep | Ea + + + + + + + + + + + + + + + + + + + |) 52 4
59 5
Printe | GGATa
CTTa
id February
Status:
Ya -
T -
T -
LZa -
T -
LZa -
T -
E -
ATa - | + 60
3, 2023 2
Patient
Isolat
Fitt
220 G
28 df
38 l2
28 df
46 A
53 E | ESC
GRT
GRT
C
GRT
P
P
P
P
P
P
P
P
P
P
P
P
P
P
P
P
P
P
P |
| 54 SCLT0 4- 55 541 WEICOL 4- 55 543 Mericol Consomer: 62 544 Mericol Consomer: 56 547 Selected Organism: Late ID-4 Selected Organism: 548 Selected Organism: E E 549 Selected Organism: E E 540 Mennetification Information: Selected Organism: E 10 Analysis Messages: E E E 110 Analysis Messages: 2 B B 2 3 13 3 3 3 3 9 B 4 2 3 3 9 8 4 2 3 3 9 9 8 4 3 2 9 9 8 4 4 3 1 4 4 4 4 4 4 4 4 4 4 4 4 4<
 |
MACAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MAR | - 566
- 63
- 63
- 63
- 63
- 63
- 63
- 63
- | LATA
NAGA
Microbiol
Microbiol
Microbiol
PhiProbability
PhiProbability
PhiProbability
MARA
450E
NAGA
KABA
450E
NAGA
KABA
450E
NAGA
KABA
450E
NAGA
KABA
450E
NAGA
KABA
450E
NAGA
KABA
450E
NAGA
450E
NAGA
450E
NAGA
450E
NAGA
450E
NAGA
450E
NAGA
450E
NAGA
450E
NAGA
450E
NAGA
450E
NAGA
450E
NAGA
450E
NAGA
450E
NAGA
450E
NAGA
450E
NAGA
450E
NAGA
450E
NAGA
450E
NAGA
450E
NAGA
450E
NAGA
450E
NAGA
450E
NAGA
450E
NAGA
450E
NAGA
450E
NAGA
450E
NAGA
450E
NAGA
450E
NAGA
450E
NAGA
450E
NAGA
450E
NAGA
450E
NAGA
450E
NAGA
450E
NAGA
450E
NAGA
450E
NAGA
450E
NAGA
450E
NAGA
450E
NAGA
450E
NAGA
450E
NAGA
450E
NAGA
450E
NAGA
450E
NAGA
450E
NAGA
450E
NAGA
450E
NAGA
450E
NAGA
450E
NAGA
450E
NAGA
450E
NAGA
450E
NAGA
450E
NAGA
450E
NAGA
450E
NAGA
450E
NAGA
450E
NAGA
450E
NAGA
450E
NAGA
450E
NAGA
450E
NAGA
450E
NAGA
450E
NAGA
450E
NAGA
450E
NAGA
450E
NAGA
450E
NAGA
450E
NAGA
450E
NAGA
450E
NAGA
450E
NAGA
450E
NAGA
450E
NAGA
450E
NAGA
450E
NAGA
450E
NAGA
450E
NAGA
450E
NAGA
450E
NAGA
450E
NAGA
450E
NAGA
450E
NAGA
450E
NAGA
450E
NAGA
450E
NAGA
450E
NAGA
450E
NAGA
450E
NAGA
450E
NAGA
450E
NAGA
450E
NAGA
450E
NAGA
450E
NAGA
450E
NAGA
450E
NAGA
450E
NAGA
450E
NAGA
450E
NAGA
450E
NAGA
450E
NAGA
450E
NAGA
450E
NAGA
450E
NAGA
450E
NAGA
450E
NAGA
450E
NAGA
450E
NAGA
450E
NAGA
450E
NAGA
450E
NAGA
450E
NAGA
450E
NAGA
450E
NAGA
450E
NAGA
450E
NAGA
450E
NAGA
450E
NAGA
450E
NAGA
450E
NAGA
450E
NAGA
450E
NAGA
450E
NAGA
450E
NAGA
100
NAGA
100
NAGA
100
NAGA
100
NAGA
100
NAGA
100
NAGA
100
NAGA
100
NAGA
100
NAGA
100
NAGA
100
NAGA
100
NAGA
100
NAGA
100
NAGA
100
NAGA
100
NAGA
100
NAGA
100
NAGA
100
NAGA
100
NAGA
100
NAGA
100
NAGA
100
NAGA
100
NAGA
100
NAGA
100
NAGA
100
NAGA
100
NAGA
100
NAGA
100
NAGA
100
NAGA
100
NAGA
100
NAGA
100
NAGA
100
NAGA
100
NAGA
100
NAGA
100
NAGA
100
NAGA
100
NAGA
100
NAGA
100
NAGA
100
NAGA
100
NAGA
100
NAGA
100
NAGA
100
NAGA
100
NAGA
100
NAGA
100
NAGA
100
NAGA
100
NAGA
100
NAGA
100
NAGA
100
NAGA
100
NAGA
100
NAGA
100
NAGA
100
NAGA
100
NAGA
100
NAGA
100
NAGA
100
NAGA
100
NAGA
100
NAGA
100
NAGA
100
NAGA
100
NAGA
100
NAGA
100
NAGA
100
NA | + 58
- 64
- 7
- 18
- 7
- 18
- 8
- 33
- 44
- 33
- 44
- 31
- 58
- 33
- 44
- 11
- 58
- 33
- 44
- 11
- 58
- 33
- 44
- 11
- 58
- 51
- 5 | ACEa dGNTa dGNTa dGNTa Report GReport Gadda Iso GReport Gadda Iso GReport ARG + I MARY + I MELa - I ACEa + I ARG + I MHEA - I ACEa + I HARA - I HARA - I HOTORY: - J Jub | + 59
Pr
- 10
10
19
27
34
45
52
59

 | CTTa initial February IStatus: IRYA AGAINA AGAINA INITIAL AGAINA I | 60
1, 2033 2.3
Parices I
Posters I
Final
12 0.1
20 0.2
20 0.2
 | GRTm (+)
D: EVERTIN
Provision
Number: 1
Collected
VLa -
Number: 1
VLa -
Number: 1
Collected
VLa -
Number: 1
Collected
VLa -
Number: 1
Number: 1
Collected
VLa -
Number: 1
Number: 1 | 54 102.Ta bioMetricex Customer bioMetricex Customer Patient Name: V47 Locition 3: Preprint Question 4: Commertie: Commertie: Identification Information Selected Organian ID Analysis Memory Biochemical Details 3 Type 4. (2) 21 dotAl 4. (2) 22 dotAl 4. (2) 23 RRAA 4. (2) 24 drUka 2. (2) 24 drUka 2. (2) 24 drUka 2. (2) 24 drUka 2. (2) 25 drUka 2. (2) 26 DRUka 2. (2) 27 drUka 2. (2) 28 RUKA 2. (2) 29 DRUka 2. (2) 20 drUka 2. (2) 21 drUka 2. (2) 22 drUka 2. (2) 23 DRUka 2. (2) 24 drUka 2. (2) 25 DRUka 2. (2) 26 DRUka 2. (2)
 | 55 i. 62 i. i i adda glaber glaber i i 4 INN 41 INN 42 I.N. 40 KC 43 J.N. 44 M.N. 45 J.N. 46 Z.X. | 4XYLa + 4
XXGa + 4
T
T
ata
LTa - 4
CAG - 4 | 56 L 63 N Mic 35% 93% Prof 15 ARR/1 24 Max 43 d400 56 LATA 63 NAC | Time:
Time:
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tabability
tababil | S8 ACC 18.20 Ca 64 AGC 18.20 Ca 66046 Ca 7 ARG 81 AAY 18 AAY 18 AAY 19 AAY 10 IAVA 10 IAVA 11 AAY 12 IAVA 13 IARA 14 AAC 15 IAVA 16 AAY 17 ARG 18 IAVA 19 IAVA 10 IAVA 10 <td< td=""><td>Ea + + + + + + + + + + + + + + + + + + +</td><td>) 52 4
59 5
Printe</td><td>GGATa
CTTa
id February
Status:
Ya -
T -
T -
LZa -
T -
LZa -
T -
E -
ATa -</td><td>+ 60
3, 2023 2
Patient
Isolat
Fitt
220 G
28 df
38 l2
28 df
46 A
53 E</td><td>ESC
GRT
GRT
C
GRT
P
P
P
P
P
P
P
P
P
P
P
P
P
P
P
P
P
P
P</td></td<> | Ea + + + + + + + + + + + + + + + + + + + |) 52 4
59 5
Printe | GGATa
CTTa
id February
Status:
Ya -
T -
T -
LZa -
T -
LZa -
T -
E -
ATa - | + 60
3, 2023 2
Patient
Isolat
Fitt
220 G
28 df
38 l2
28 df
46 A
53 E | ESC
GRT
GRT
C
GRT
P
P
P
P
P
P
P
P
P
P
P
P
P
P
P
P
P
P
P
 |
| 54 SCLT0 4- 55 541 WEICOL 4- 55 543 Mericol Consomer: 62 544 Mericol Consomer: 56 547 Selected Organism: Late ID-4 Selected Organism: 548 Selected Organism: E E 549 Selected Organism: E E 540 Mennetification Information: Selected Organism: E 10 Analysis Messages: E E E 110 Analysis Messages: 2 B B 2 3 13 3 3 3 3 9 B 4 2 3 3 9 8 4 2 3 3 9 9 8 4 3 2 9 9 8 4 4 3 1 4 4 4 4 4 4 4 4 4 4 4 4 4<
 |
MACAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MAR | - 566
- 63
- 63
- 63
- 63
- 63
- 63
- 63
- | LATA
NAGA
Microbiol
Microbiol
Microbiol
National Antiparticity
Science States
Markan
ARBa
ARBa
ARBA
ARBA
ARBA
ARBA
ARBA
ARBA | + 58
- 64
- 7
- 18
- 7
- 18
- 8
- 33
- 44
- 33
- 44
- 31
- 58
- 33
- 44
- 11
- 58
- 33
- 44
- 11
- 58
- 33
- 44
- 11
- 58
- 51
- 5 | محلة المحلة | + 59
Pr
- 10
10
19
27
34
45
52
59

 | CTTa initial February IStatus: IRYA AGAINA AGAINA INITIAL AGAINA I | 60
3, 2033 2.3
Patient Is
Fund
Fund
12 k012
28 k0
46 A0
40 k0
29 k
40 k0
40 | CRTm (*) CRTm (*) SII 2 PM AST SII 2 PM AST SII 2 PM AST Collected
 | 54 IGLTs i bioMericaex Customers bioMericaex Customers Drainen Nourty: Developments: Comments: Comments: Identification Informa Selected Organism IB Analysis Message Biodrafication Informa Selected Organism IB Analysis Message Biodrafication Informa 29 BRJAa 29 BRJAa 29 BRJAa 24 IOLTa 25 IOLTa 24 IOLTa 25 IOLTa 26 IOLTa 27 ATUGA 28 IOLTa 29 Chart Report
 | 55 i. 62 i. a i. a i. a i. a i. b i. a i. b i. b i. b i. c i. b i. b i. b i. b i. c i. c i. b i. c i. | AXYLa +
XKGa +
F
F
xtta +
xtta | 56 L 63 N Mic 35% 93% Prof 15 ARR/1 24 Max 43 d400 56 LATA 63 NAC | Time: - | S8 ACC 18.20 Ca 64 AGC 18.20 Ca 66046 Ca 7 ARG 81 AAY 18 AAY 18 AAY 19 AAY 10 IAY 11 AAY 12 IAAA 13 IARA 14 AAC 15 IARA 16 AAY 17 ARG 18 AAY 19 Mate 10 HV 10 HV 1 | Ea + + + + + + + + + + + + + + + + + + + |) 52 4
59 5
Printe | GGATa
CTTa
id February
Status:
Ya -
T -
T -
LZa -
T -
LZa -
T -
E -
ATa - | + 60
3, 2023 2
Patient
Isolat
Fitt
220 G
28 df
38 l2
28 df
46 A
53 E | ESC
GRT
GRT
C
GRT
P
P
P
P
P
P
P
P
P
P
P
P
P
P
P
P
P
P
P
 |
| 54 SCLT0 4- 55 541 WEICOL 4- 55 543 Mericol Consomer: 62 544 Mericol Consomer: 56 547 Selected Organism: Late ID-4 Selected Organism: 548 Selected Organism: E E 549 Selected Organism: E E 540 Mennetification Information: Selected Organism: E 10 Analysis Messages: E E E 110 Analysis Messages: 2 B B 2 3 13 3 3 3 3 9 B 4 2 3 3 9 8 4 2 3 3 9 9 8 4 3 2 9 9 8 4 4 3 1 4 4 4 4 4 4 4 4 4 4 4 4 4<
 |
MACAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MAR | - 566
- 63
- 63
- 63
- 63
- 63
- 63
- 63
- | Lefa NAGa Microbiol and State | + 58
- 64
- 64
- 7
- 1
- 7
- 18
- 8
- 8
- 8
- 8
- 8
- 9
- 9
- 9
- 9
- 9
- 9
- 9
- 9 | الته المحافظة محافظة المحافظة محافظة محافظة محافظة محافظة محافظة محافظة محافظة محافظة محافظة محافظة
محافظة محافظة المحافظة المحافظة المحافظة المحافظة المحافظة المحافظة محافظة محافظة محافظة محافظة محافظة محافظة مح
محافظة محافظة محاف | + 59
Pr
- 10
10
19
27
34
45
52
59

 | CTTa initial February IStatus: IRYA AGAINA AGAINA INITIAL AGAINA I | 60
3, 2033 2.3
Patient Is
Fund
Fund
12 k012
28 k0
46 A0
53 k3
53 k3
54 k0
64 A0
40 k0
4
54 k0
55 k0 | Collected:
212 PMAST
D: BWAST
D: BWAST
Provision
Number: 1
Collected:
 | 54 IGLTs i bidMerican Customer i IPROA i bidMerican Customer i IProblem Numer: V47 Lat 10: 20 Preparise Quantity: Selected Organism : Car Conneents: Commerts: Meetification Informa Selected Organism ID Analysis Message ID Analysis Message 21 dGLLTa - 22 dGLLTa - 23 IRTA - 24 IGLTa - 32 JAA - 34 IGLTa - 35 IGLTa - 36 IGLTa - 37 IGLTa - 36 IGLTa -
 | 55 i. 62 i. a i. a i. a i. a i. b i. a i. b i. b i. b i. c i. b i. b i. b i. b i. c i. c i. b i. c i. | AXYLa +
XKGa +
F
F
xtta +
xtta | 56 L 0.3 N Mic Mic 93:s Prob 13 ARII 14 Mic 15 Leach 16 ARII 17 ARII 18 Mic 19 Pril 19 Pril 10 NAC Pril 26, 21 | NTA - AGa - Time: - bability - a - bability - a - a - a - bability - Bab - D229.09/J.3 - Isolat - Final - | S8 ACC 18.20 Ca 64 AGC 18.20 Ca 66046 Ca 7 ARG 81 AAY 18 AAY 18 AAY 19 AAY 10 IAY 11 AAY 12 IAAA 13 IARA 14 AAC 15 IARA 16 AAY 17 ARG 18 AAY 19 Mate 10 HV 10 HV 1 | Ea + + + + + + + + + + + + + + + + + + + |) 52 4
59 5
Printe | GGATa
CTTa
id February
Status:
Ya -
T -
T -
LZa -
T -
LZa -
T -
E -
ATa - | + 60
3, 2023 2
Patient
Isolat
Fitt
220 G
28 df
38 l2
28 df
46 A
53 E | ESC
GRT
GRT
C
GRT
P
P
P
P
P
P
P
P
P
P
P
P
P
P
P
P
P
P
P
 |
| 54 SCLT0 4- 55 541 WEICOL 4- 55 543 Mericol Consomer: 62 544 Mericol Consomer: 56 547 Selected Organism: Late ID-4 Selected Organism: 548 Selected Organism: E E 549 Selected Organism: E E 540 Mennetification Information: Selected Organism: E 10 Analysis Messages: E E E 110 Analysis Messages: 2 B B 2 3 13 3 3 3 3 9 B 4 2 3 3 9 8 4 2 3 3 9 9 8 4 3 2 9 9 8 4 4 3 1 4 4 4 4 4 4 4 4 4 4 4 4 4<
 |
MACAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MAR | - 566
- 63
- 63
- 63
- 63
- 63
- 63
- 63
- | LATA
NAGA
Microbiol
ualysis Tame:
55 Potabality
isounder:
1 Lean 1
NAGA
MAGA
MAGA
MAGA
MAGA
MAGA
MAGA
MAGA | - 58
- 64
- 7
- 7
- 7
- 7
- 8
- 8
- 96
- 33
- 44
- 15
- 33
- 44
- 53
- 33
- 44
- 53
- 33
- 44
- 53
- 33
- 44
- 58
- 58 | الته المحافظة محافظة المحافظة محافظة محافظة محافظة محافظة محافظة محافظة محافظة محافظة محافظة محافظة
محافظة محافظة المحافظة المحافظة المحافظة المحافظة المحافظة المحافظة محافظة محافظة محافظة محافظة محافظة محافظة مح
محافظة محافظة محاف | + 59
- 59
- 10
10
19
27
34
45
52
59
- 1
- 10
- 10
 | CTD
Inter Televisy
Status:
Status:
Status:
Status:
CTD
Inter I
Inter Inter Inter I
Inter Inter | 60
3, 3027 2, 3
Patient I
Fondat
Final
12 022 02
13 05
14 04
15 05
15 404
15 10
15 404
16 05
17 10
18 10
18 10
19 10
10 0
10 0
 | ORTen (-) DETERMANT DETERMANT DETERMANT DETERMANT DETERMANT DETERMANT Provision VLa Namber VLa Namber VLa Namber VLa VLa VLa VLa VLA VLA VLA VI Tas VI Itorobiology Itorobability Namber: 10.93 hours | 54 IGLTs i bidMerican Customer i IPRO. i bidMerican Customer i I I i I i I i I i I i I i I i I i I i I i I<
 | 55 62 62 2 addala glaber ation 14 14 100 123 LAV 30 NA 40 XI 30 NA 40 XI 55 4X 55 4X 62 2K | AXYLa +
XKGa +
F
F
xtta +
xtta | 56 L 0.3 N Mic Mic 93:5 N 93:5 N 93:5 N 13 AM 15 Law 15 AMI 16 NAC 56 LAT 63 NAC 97:1 26, 27 15 Law 16 NAC 17 Status: | ATA - AGa - Time: - bability - a - bability - a - a - a - bability
 | 35 AK 94 400 18.20 Chart Rep 18.20 Chart Rep 7 ABG 18 ACAT 7 ABG 18 AMY 64 400 7 ABG 18 AAS 84 AGN 101 102 1 LARA | Ea - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - |) 52 4
59 5
Printe | GGATa
CTTa
id February
Status:
Ya -
T -
T -
LZa -
T -
LZa -
T -
E -
ATa - | + 60
3, 2023 2
Patient
Isolat
Fitt
220 G
28 df
38 l2
28 df
46 A
53 E | ESC
GRT
GRT
ID: E
P
P
P
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C |
| 54 SCLT0 4- 55 541 WEICOL 4- 55 543 Mericol Consomer: 62 544 Mericol Consomer: 56 547 Selected Organism: Late ID-4 Selected Organism: 548 Selected Organism: E E 549 Selected Organism: E E 540 Mennetification Information: Selected Organism: E 10 Analysis Messages: E E E 110 Analysis Messages: 2 B B 2 3 13 3 3 3 3 9 B 4 2 3 3 9 8 4 2 3 3 9 9 8 4 3 2 9 9 8 4 4 3 1 4 4 4 4 4 4 4 4 4 4 4 4 4<
 |
MACAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MAR | - 566
- 63
- 63
- 63
- 63
- 63
- 63
- 63
- | LATA
NAGA
Microbiol
Microbiol
National Anna - Anna | Ss 64 | الت المحمد ا
لمحمد المحمد المحم
محمد المحمد محمد المحمد المحمم | + 59

 | CTD
Status:
Status:
Status:
Status:
Status:
Status:
Status:
Status:
Status:
Status:
Status:
Status:
Status:
Status:
Status:
Status:
Status:
Status:
Status:
Status:
Status:
Status:
Status:
Status:
Status:
Status:
Status:
Status:
Status:
Status:
Status:
Status:
Status:
Status:
Status:
Status:
Status:
Status:
Status:
Status:
Status:
Status:
Status:
Status:
Status:
Status:
Status:
Status:
Status:
Status:
Status:
Status:
Status:
Status:
Status:
Status:
Status:
Status:
Status:
Status:
Status:
Status:
Status:
Status:
Status:
Status:
Status:
Status:
Status:
Status:
Status:
Status:
Status:
Status:
Status:
Status:
Status:
Status:
Status:
Status:
Status:
Status:
Status:
Status:
Status:
Status:
Status:
Status:
Status:
Status:
Status:
Status:
Status:
Status:
Status:
Status:
Status:
Status:
Status:
Status:
Status:
Status:
Status:
Status:
Status:
Status:
Status:
Status:
Status:
Status:
Status:
Status:
Status:
Status:
Status:
Status:
Status:
Status:
Status:
Status:
Status:
Status:
Status:
Status:
Status:
Status:
Status:
Status:
Status:
Status:
Status:
Status:
Status:
Status:
Status:
Status:
Status:
Status:
Status:
Status:
Status:
Status:
Status:
Status:
Status:
Status:
Status:
Status:
Status:
Status:
Status:
Status:
Status:
Status:
Status:
Status:
Status:
Status:
Status:
Status:
Status:
Status:
Status:
Status:
Status:
Status:
Status:
Status:
Status:
Status:
Status:
Status:
Status:
Status:
Status:
Status:
Status:
Status:
Status:
Status:
Status:
Status:
Status:
Status:
Status:
Status:
Status:
Status:
Status:
Status:
Status:
Status:
Status:
Status:
Status:
Status:
Status:
Status:
Status:
Status:
Status:
Status:
Status:
Status:
Status:
Status:
Status:
Status:
Status:
Status:
Status:
Status:
Status:
Status:
Status:
Status:
Status:
Status:
Status:
Status:
Status:
Status:
Status:
Status:
Status:
Status:
Status: | 60
3, 3027 2, 3
Patient I
Fondat
Final
12 022 02
13 05
14 04
15 05
15 404
15 10
15 404
16 05
17 10
18 10
18 10
19 10
10 0
10 0
 | Collected:
212 PMAST
D: BWAST
D: BWAST
Provision
Number: 1
Collected: | 54 102.75 bioMetrica Customer bioMetrica Customer Pattern Neme: V47 Location "panning Quantity: Comments: Comments: Dischemical Details 3 Location 12 Analysis Messages Biochemical Details 3 12 AdALS 23 AdALS 47 ATUBA 47 ATUBA 47 ATUBA 47 TUBA 54 BETA 54 BETA 61 PROA 70 Lattr Report 17.78 <hours< td=""> Candida cif 6543774775</hours<>
 | 55 62 62 2 addala glaber ation 14 14 100 123 LAV 30 NA 40 XI 30 NA 40 XI 55 4X 55 4X 62 2K | AXYLa +
XKGa +
F
F
xtta +
xtta | 56 L 0.3 N Mic Mic 93:s Prob 13 ARII 14 Mic 15 Leach 16 ARII 17 ARII 18 Mic 19 Pril 19 Pril 10 NAC Pril 26, 21 | ATA - AGa - Time: - bability - a - bability - a - a - a - bability | S8 ACC 18.20 Ca 64 AGC 18.20 Ca 66046 Ca 7 ARG 81 AAY 18 AAY 18 AAY 19 AAY 10 IAY 11 AAY 12 IAAA 13 IARA 14 AAC 15 IARA 16 AAY 17 ARG 18 AAY 19 Mate 10 HV 10 HV 1 | Ea - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 -
 |) 52 4
59 5
Printe | GGATa
CTTa
id February
Status:
Ya -
T -
T -
LZa -
T -
LZa -
T -
E -
ATa - | + 60
3, 2023 2
Patient
Isolat
Fitt
220 G
28 df
38 l2
28 df
46 A
53 E | SULVLA
SEE A
SEE A
S |
| 54 SCLT0 4- 55 541 WEICOL 4- 55 543 Mericol Consomer: 62 544 Mericol Consomer: 56 547 Selected Organism: Late ID-4 Selected Organism: 548 Selected Organism: E E 549 Selected Organism: E E 540 Mennetification Information: Selected Organism: E 10 Analysis Messages: E E E 110 Analysis Messages: 2 B B 2 3 13 3 3 3 3 9 B 4 2 3 3 9 8 4 2 3 3 9 9 8 4 3 2 9 9 8 4 4 3 1 4 4 4 4 4 4 4 4 4 4 4 4 4< | MACAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MAR | - 566
- 63
- 63
- 63
- 63
- 63
- 63
- 63
- | LATA
NAGA
Microbiol
andysis Time:
75 Pubahaligi
and the second second
second second second second
second second second second
second second second second
second second second second second
second second second second second
second second second second second
second second second second second second
second second second second second second
second second second second second second second
second second second second second second second
second second second second second second second second second
second second se | s Ss
ogy Char
ogy Char
c Char | الدي
المحافظة المحافظة المح
محافظة المحافظة المحاف
محافظة محافظة المحافظة محافظة محافي
محافظة محافظة المحافظة المحافظة المحافظة المحافظة المحافظة محافظة مح
محافظة محافظة المحافظة المحافظة محاضي محافظة محافظ | + 59
 | CTD
Inter Televisy
Status:
Status:
Status:
Status:
CTD
Inter I
Inter Inter Inter I
Inter Inter | 69 3, 3027 2.3 Patient I Final 12 20 21 22 23 24 25 26 27 28 29 20 20 20 20 20 20 20 20 20 20 20 <td>ORTen (-) DETERMANT DETERMANT DETERMANT DETERMANT DETERMANT DETERMANT Provision VLa Namber VLa Namber VLa Namber VLa VLa VLa VLa VLA VLA VLA VI Tas VI Itorobiology Itorobability Namber: 10.93 hours</td> <td>54 102.Ta 101 1990.0 bioMetricex Customers Patient Name: V47 Lociton 3: Preprint Quartity: Person Quartity: Intern Name: V47 Lociton 3: Preprint Quartity: Intern Name: V47 Comments: Intern Name: V47 Selected Organism ID Auslysis Messages Biodemical Details 3 Type A 13 Type A 21 40.UL # 22 40.EXT = 4 47.UL # 24 47.UL # 25 40.UL # 26 10.EXT = 26 10.EXT = 26 10.EXT = 27 40.UL # 28 10.EXT = 29 10.EXT = 20 10.EXT = 21<td>55 62 62 2 addala glaber ation 14 14 100 123 LAV 30 NA 40 XI 30 NA 40 XI 55 4X 55 4X 62 2K</td><td>AXYLa +
XKGa +
F
F
xtta +
xtta +
xtta</td><td>56 L 0.3 N Mic Mic 93:5 N 93:5 N 93:5 N 13 AM 15 Law 15 AMI 16 NAC 56 LAT 63 NAC 97:1 26, 27 15 Law 16 NAC 17 Status:</td><td>ATA - AGa - Time: - bability - a - bability - a - a - a - bability - Bability</td><td>35 AK 94 400 18.20 Chart Rep 18.20 Chart Rep 7 ABG 7 ABG 8 ACC 9 3 dMEL 9 AMY 9 ACONE 9 AMY 9 ACC 9 ACONE 1 1</td><td>Ea - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 -</td><td>) 52 4
59 5
Frinte</td><td>GGATa
CTTa
id February
Status:
Ya -
T -
T -
LZa -
T -
LZa -
T -
E -
ATa -</td><td>+ 60
3, 2023 2
Patient
Isolat
Fitt
220 G
28 df
38 l2
28 df
46 A
53 E</td><td>SULVLA
SEE A
SEE A
S</td></td> | ORTen (-) DETERMANT DETERMANT DETERMANT DETERMANT DETERMANT DETERMANT Provision VLa Namber VLa Namber VLa Namber VLa VLa VLa VLa VLA VLA VLA VI Tas VI Itorobiology Itorobability Namber: 10.93 hours | 54 102.Ta 101 1990.0 bioMetricex Customers Patient Name: V47 Lociton 3: Preprint Quartity: Person Quartity: Intern Name: V47 Lociton 3: Preprint Quartity: Intern Name: V47 Comments: Intern Name: V47 Selected Organism ID Auslysis Messages Biodemical Details 3 Type A 13 Type A 21 40.UL # 22 40.EXT = 4 47.UL # 24 47.UL # 25 40.UL # 26 10.EXT = 26 10.EXT = 26 10.EXT = 27 40.UL # 28 10.EXT = 29 10.EXT = 20 10.EXT = 21 <td>55 62 62 2 addala glaber ation 14 14 100 123 LAV 30 NA 40 XI 30 NA 40 XI 55 4X 55 4X 62 2K</td> <td>AXYLa +
XKGa +
F
F
xtta +
xtta +
xtta</td> <td>56 L 0.3 N Mic Mic 93:5 N 93:5 N 93:5 N 13 AM 15 Law 15 AMI 16 NAC 56 LAT 63 NAC 97:1 26, 27 15 Law 16 NAC 17 Status:</td> <td>ATA - AGa - Time: - bability - a - bability - a - a - a - bability - Bability</td> <td>35 AK 94 400 18.20 Chart Rep 18.20 Chart Rep 7 ABG 7 ABG 8 ACC 9 3 dMEL 9 AMY 9 ACONE 9 AMY 9 ACC 9 ACONE 1 1</td> <td>Ea - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 -</td> <td>) 52 4
59 5
Frinte</td> <td>GGATa
CTTa
id February
Status:
Ya -
T -
T -
LZa -
T -
LZa -
T -
E -
ATa -</td> <td>+ 60
3, 2023 2
Patient
Isolat
Fitt
220 G
28 df
38 l2
28 df
46 A
53 E</td> <td>SULVLA
SEE A
SEE A
S</td> | 55 62 62 2 addala glaber ation 14 14 100 123 LAV 30 NA 40 XI 30 NA 40 XI 55 4X 55 4X 62 2K | AXYLa +
XKGa +
F
F
xtta +
xtta | 56 L 0.3 N Mic Mic 93:5 N 93:5 N 93:5 N 13 AM 15 Law 15 AMI 16 NAC 56 LAT 63 NAC 97:1 26, 27 15 Law 16 NAC 17 Status: | ATA - AGa - Time: - bability - a - bability - a - a - a - bability | 35 AK 94 400 18.20 Chart Rep 18.20 Chart Rep 7 ABG 7 ABG 8 ACC 9 3 dMEL 9 AMY 9 ACONE 9 AMY 9 ACC 9 ACONE 1 1 | Ea - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - |) 52 4
59 5
Frinte | GGATa
CTTa
id February
Status:
Ya -
T -
T -
LZa -
T -
LZa -
T -
E -
ATa - | + 60
3, 2023 2
Patient
Isolat
Fitt
220 G
28 df
38 l2
28 df
46 A
53 E | SULVLA
SEE A
SEE A
S |
| 54 SCLT0 4- 55 541 WEICOL 4- 55 543 Mericol Consomer: 62 544 Mericol Consomer: 56 547 Selected Organism: Late ID-4 Selected Organism: 548 Selected Organism: E E 549 Selected Organism: E E 540 Mennetification Information: Selected Organism: E 10 Analysis Messages: E E E 110 Analysis Messages: 2 B B 2 3 13 3 3 3 3 9 B 4 2 3 3 9 8 4 2 3 3 9 9 8 4 3 2 9 9 8 4 4 3 1 4 4 4 4 4 4 4 4 4 4 4 4 4<
 |
MACAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MAR | - 566
- 63
- 63
- 63
- 63
- 63
- 63
- 63
- | LATA
NAGA
Microbiol
Microbiol
Nicrobiol
Lent To
Strandard
Marka
NaGa
Lath D
Comm
Selecte
Source
Comm
Identification
Selecte
ID Ani | s Ss
ogy Char
ogy Char
c Char | الدي
المحافظة المحافظة المح
محافظة المحافظة المحاف
محافظة محافظة المحافظة محافظة محافي
محافظة محافظة المحافظة المحافظة المحافظة المحافظة المحافظة محافظة مح
محافظة محافظة المحافظة المحافظة محاضي محافظة محافظ | + 59
 | CITa
Status
Status
ERVia -
Status
RVia -
Status
RVia -
Status
RVia -
RVia -
RVi | 69 3, 3027 2.3 Patient I Final 12 20 20 20 20 20 20 20 20 20 20 20
 20 20 20 20 20 20 20 20 20 20 20 20 20 20 20 20 21 22 23 24 25 26 27 28 29 20 20 20 20 20 20 20 20 20 20 20 <td>Callese ()
21:2 PM ANT
D. EWORTEN
Projekiane
Collected:</td> <td>54 102.Th bidMetricex Customer bidMetricex Customer Disconserve Commerts: Disconserve Commerts: Commerts: Identification Information Selected Organism ID Analysis Messages 10 Analysis Messages 20 dRUATa 20 dRUATa 20 dRUATa 20 dRUATa 20 dRUATa 21 TypeA 22 dRUATa 23 dRUATa 24 dRUATa 25 dRUATa 26 dRUATa 27 dTUUa 41 dRUATa 28 dRUATa 29 dRUATa 20 dRUATa 20 dRUATa 21 dRUATa 22 dRUATA 23 dRUATA 24 dRUATa 25 dRUATA 26 dRUATA 27 dTUUa 4 dRUATA 28 dRUATA 29 dRUATA 20 dRUATA 20 dRUATA 21 dRUATA 22 dR</td> <td>55 62 62 2 addala glaber ation 14 14 100 123 LAV 30 NA 40 XI 30 NA 40 XI 55 4X 55 4X 62 2K</td> <td>AXYLa +
XKGa +
F
F
xtta +
xtta +
xtta</td> <td>56 L 0.3 N Mic Mic 325 Pope 15 Leadysis 80 NA 325 Pope 325 Pope 32 Max 32 Max 32 MAX 32 MAX 33 Galaxia 34 NO3 35 LCACK 38 LCACK 40 NO3 36 LCACK Value NO3 36 LCACK Value NO3 36 LCACK Value NO3 36 LCACK Value NO3 39 LCACK Value NO3 Status: NO3 Value NO3 NO4 NO3 Status: NO4</td> <td>ATA - AGa - Time: - bability - a - bability - a - a - a - bability - Bability</td> <td>IS AK IS.20 Chart Rep IS.20 Ca IS.20 AMG IS.20</td> <td>Ea - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 -</td> <td>) 52 4
59 5
Frinte</td> <td>GGATa
CTTa
id February
Status:
Ya -
T -
T -
LZa -
T -
LZa -
T -
E -
ATa -</td> <td>+ 60
3, 2023 2
Patient
Isolat
Fitt
220 G
28 df
38 l2
28 df
46 A
53 E</td> <td>SULVLA
SEE A
SEE A
S</td> | Callese ()
21:2 PM ANT
D. EWORTEN
Projekiane
Collected: | 54 102.Th bidMetricex Customer bidMetricex Customer Disconserve Commerts: Disconserve Commerts: Commerts: Identification Information Selected Organism ID Analysis Messages 10 Analysis Messages 20 dRUATa 20 dRUATa 20 dRUATa 20 dRUATa 20 dRUATa 21 TypeA 22 dRUATa 23 dRUATa 24 dRUATa 25 dRUATa 26 dRUATa 27 dTUUa 41 dRUATa 28 dRUATa 29 dRUATa 20 dRUATa 20 dRUATa 21 dRUATa 22 dRUATA 23 dRUATA 24 dRUATa 25 dRUATA 26 dRUATA 27 dTUUa 4 dRUATA 28 dRUATA 29 dRUATA 20 dRUATA 20 dRUATA 21 dRUATA 22 dR
 | 55 62 62 2 addala glaber ation 14 14 100 123 LAV 30 NA 40 XI 30 NA 40 XI 55 4X 55 4X 62 2K | AXYLa +
XKGa +
F
F
xtta +
xtta | 56 L 0.3 N Mic Mic 325 Pope 15 Leadysis 80 NA 325 Pope 325 Pope 32 Max 32 Max 32 MAX 32 MAX 33 Galaxia 34 NO3 35 LCACK 38 LCACK 40 NO3 36 LCACK Value NO3 36 LCACK Value NO3 36 LCACK Value NO3 36 LCACK Value NO3 39 LCACK Value NO3 Status: NO3 Value NO3 NO4 NO3 Status: NO4 | ATA - AGa - Time: - bability - a - bability - a - a - a - bability | IS AK IS.20 Chart Rep IS.20 Ca IS.20 AMG IS.20 | Ea - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 -
 |) 52 4
59 5
Frinte | GGATa
CTTa
id February
Status:
Ya -
T -
T -
LZa -
T -
LZa -
T -
E -
ATa - | + 60
3, 2023 2
Patient
Isolat
Fitt
220 G
28 df
38 l2
28 df
46 A
53 E | SULVLA
SEE A
SEE A
S |
| 54 SCLT0 4- 55 541 WEICOL 4- 55 543 Mericol Consomer: 62 544 Mericol Consomer: 56 547 Selected Organism: Late ID-4 Selected Organism: 548 Selected Organism: E E 549 Selected Organism: E E 540 Mennetification Information: Selected Organism: E 10 Analysis Messages: E E E 110 Analysis Messages: 2 B B 2 3 13 3 3 3 3 9 B 4 2 3 3 9 8 4 2 3 3 9 9 8 4 3 2 9 9 8 4 4 3 1 4 4 4 4 4 4 4 4 4 4 4 4 4<
 |
MACAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MARCAL
MAR | - 566
- 63
- 63
- 63
- 63
- 63
- 63
- 63
- | LATA
NAGA
Microbiol
Microbiol
Nicrobiol
Lenk 1 - 1
ABBa - 1
Strabability
seember:
Lenk 1 - 1
ABBa - 1
Strabability
seember:
Strabability
MAGA - 1
Strabability
Steete
Source
Comm
Identifi
Selecte
ID Ann
Voricoutor | s Sa Galanti Sa | الدي
المحافظة المحافظة المح
محافظة المحافظة المحاف
محافظة محافظة المحافظة محافظة محافي
محافظة محافظة المحافظة المحافظة المحافظة المحافظة المحافظة المحافظة محافظة محافظة محافظة محافظة محافظة محافظة محافظة محافظة المحافظة المح
محافظة محافظة المحافظة المحافظة المحافظة المحافظة ا |
 | CITa
Status
Status
ERVia -
Status
RVia -
Status
RVia -
Status
RVia -
RVia -
RVi | 69 3, 3023 2, 3 Patient I Fondat Fundat Fundat Fundat Fundat Fundat Fundat Fundat Fundat Fundat Fundat Fundat Fundat Fundat Fundat Fundat Fundat Fundat Fundat Fundat Fundat Fundat Fundat Fun
 | Callese ()
21:2 PM ANT
D. EWORTEN
Projekiane
Collected: | 54 102.Ta 101 1990.0 bioMetricex Customers Patient Name: V47 Lociton 3: Preprint Quartity: Person Quartity: Intern Name: V47 Lociton 3: Preprint Quartity: Intern Name: V47 Comments: Intern Name: V47 Selected Organism ID Auslysis Messages Biodemical Details 3 Type A 13 Type A 21 40.UL # 22 40.EXT = 4 47.UL # 24 47.UL # 25 40.UL # 26 10.EXT = 26 10.EXT = 26 10.EXT = 27 40.UL # 28 10.EXT = 29 10.EXT = 20 10.EXT = 21 <td>55 62 62 2 addala glaber ation 14 14 100 123 LAV 30 NA 40 XI 30 NA 40 XI 55 4X 55 4X 62 2K</td> <td>AXYLa +
XKGa +
F
F
xtta +
xtta +
xtta</td> <td>56 L 0.3 N Mic Mic 325 Pope 15 Leadysis 80 NA 325 Pope 325 Pope 32 Max 32 Max 32 MAX 32 MAX 33 Galaxia 34 NO3 35 LCACK 38 LCACK 40 NO3 36 LCACK Value NO3 36 LCACK Value NO3 36 LCACK Value NO3 36 LCACK Value NO3 39 LCACK Value NO3 Status: NO3 Value NO3 NO4 NO3 Status: NO4</td> <td>NTA - ArGa - Time: - bability - a - bability - a - a - a - bability - Bability</td> <td>IS AK IS.20 Chart Rep IS.20 Ca IS.20 AMG IS.20</td> <td>Ea - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 -</td> <td>) 52 4
59 5
Frinte</td> <td>GGATa
CTTa
id February
Status:
Ya -
T -
T -
LZa -
T -
LZa -
T -
E -
ATa -</td> <td>+ 60
3, 2023 2
Patient
Isolat
Fitt
220 G
28 df
38 l2
28 df
46 A
53 E</td> <td>GRTi
30:42
t ID: E¹
PP
te Num
C
C
all
SLYLa
SENa
MALa
SBEa
GLU
SC</td> | 55 62 62 2 addala glaber ation 14 14 100 123 LAV 30 NA 40 XI 30 NA 40 XI 55 4X 55 4X 62 2K | AXYLa +
XKGa +
F
F
xtta +
xtta | 56 L 0.3 N Mic Mic 325 Pope 15 Leadysis 80 NA
 325 Pope 325 Pope 32 Max 32 Max 32 MAX 32 MAX 33 Galaxia 34 NO3 35 LCACK 38 LCACK 40 NO3 36 LCACK Value NO3 36 LCACK Value NO3 36 LCACK Value NO3 36 LCACK Value NO3 39 LCACK Value NO3 Status: NO3 Value NO3 NO4 NO3 Status: NO4 | NTA - ArGa - Time: - bability - a - bability - a - a - a - bability | IS AK IS.20 Chart Rep IS.20 Ca IS.20 AMG IS.20 | Ea - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - |) 52 4
59 5
Frinte | GGATa
CTTa
id February
Status:
Ya -
T -
T -
LZa -
T -
LZa -
T -
E -
ATa - | + 60
3, 2023 2
Patient
Isolat
Fitt
220 G
28 df
38 l2
28 df
46 A
53 E | GRTi
30:42
t ID: E ¹
PP
te Num
C
C
all
SLYLa
SENa
MALa
SBEa
GLU
SC |

Figure 3. Results of *Candida* spp. identification using VITEK 2 system.

A) C. albicans, B) C. krusei, C) C. kefyr, D) C. tropicalis, E) C. lusitaniae, G) C. glabrata, and F) C. ciferrii.

krusei. Also, pink colonies indicated C. glabrata, cream to white colonies with slight pink center indicated C. kefyr, blue to purple colonies indicated C. tropicalis, creamy to slight purple colonies indicated C. parasilosis, and white to creamy colonies indicated C. ciferii and C. lusitaniae. A different study, conducted by Bayona et al., 2020 [15], is in agreement with these results. Under microscopy, the size and shape of cells of Candida spp. were identified. The results indicated that cells of Candida were spherical or of an oval shape with budding like a yeast, which is in agreement with Al-Dabbagh et al., 2023 [10] and Bayona et al., 2020 [15]. In a study conducted by Ajah et al., 2020 [16], 41.98% of the cases (n = 56 out of 111 cases) showed positive results for Candida spp., including 56 Candida isolates from vaginal swabs, whereas the majority of isolates was C. albicans (n = 41; 73%), which is in agreement with findings of this study, followed by C. glabrata 5 (9%), krusei 2 (3.5%), and other spp. Also, there were 55 different Candida spp. isolates from oral swabs, including C. tropicalis 1(1.8%), C. krusei 2 (3.6%), and glabrata 7 (13%), while 36 (65%) were C. albicans.

In addition, it has been reported that *C. famata*, *C. glabrata*, and *C. albicans* were the most common species of yeast obtained from vaginal infection, with percentages 14.8%, 44.5%, and 45%, respectively [17].

The findings showed that C. albicans isolates produce germ tubes, which are lengthy, tube-like extensions from yeast cells, and the results indicated that the other non-C. albicans species showed to be negative, which is in agreement with Al-Dabbagh et al., 2023 [10]. After being incubated with human serum, the germ tubes produced for just two hours. After being incubated with human serum, the germ tubes produce in just two hours. All C. albicans isolates in this study had the ability to generate germ tubes when analyzed in a colony setting, which is consistent with the findings conducted by Matare et al., 2017 [18]. C. albicans can be detected rapidly to the development of germ tubes in human serum. C. albicans produce germ tubes in human serum, which causes the fungus to transform from yeast to a filamentous or mycelial growth. Fungi often respond to changing environmental conditions by undergoing morphological changes, which may help the fungus to accommodate to new biological elements. Candida albicans and C. dubliniensis are the only organisms known to have successfully formatted a germ tube [18,19].

In a study conducted by Mohammedet al., 2017 [17], it has been reported that 7 isolates were non-phospholipase producers, 2 of the isolates were strong-phospholipase producers, and 2 of the isolates were moderatephospholipase producers. Also, 87.3% (n = 48) out of 55 isolates revealed activity of phospholipase and 7 (12.7%) had no activity of phospholipase in the study conducted by Ajah et al., 2020 [16]. Released phosphorlipases are extracellular hydrolytic enzymes. According to the study conducted by Larkin et al., 2017 [20], synthesis phospholipase is dependent on the strain of producer. De Paula et al., 2016[21], reported that activity of phospholipase was detected in 99% of *C. albicans* isolates [21]. Phospholipases are enzymes that cause the breakdown of cell membranes by hydrolyzing the ester linkages in glycerophospholipids, this means phospholipases can either bind to the outside of cells or be discharged into the surrounding environment [22].

The outcomes demonstrated that biofilm development varied between strains. Biofilm production was shown to be prevalent among *Candida* spp. In agreement with this study, it has been reported that the majority (n = 10) of *Candida* species were moderate- and strong-biofilm producers [14]. Antifungal resistance in *Candida* is mainly caused by the development of biofilms. The capacity to form biofilms on abiotic and biotic surfaces has been linked to the pathogenic potential of *Candida* spp. [23].

CONCLUSION

The findings of this study suggested that the majority of *Candida* spp., especially *C. albicans*, poses a risk to human health, which may be attributed to their ability to secrete phospholipase and form biofilm.

Acknowledgment:

The authors thank Mustansiriyah University in Iraq (https://www.uomustansiriyah.edu.iq/) for their support of the present research.

Ethical Approval:

The study protocol was approved by the Ethics Committee of the Mustansiriyah University, Baghdad, Iraq.

Source of Funds:

Self-funded.

Declaration of Interest:

The authors declare that they have no conflicts of interest.

References:

- Bhattacharya S, Sae-Tia S, Fries BC. *Candidiasis* and Mechanisms of Antifungal Resistance. Antibiotics (Basel) 2020;9(6): 312. (PMID: 32526921)
- Samuel O, Ifeanyi O, Ugochukwu O. Prevalence of *Candida* species among vaginitis symptomatic pregnant women attending ante-natal clinic of Anambra State University Teaching Hospital, Awka, Nigeria. Bioengin Biosci 2015;3(2):23-7. https://www.hrpub.org/download/20150510/BB2-10103802.pdf

- Al-Baqer TM, Al-Gharrawi SAR, Saeed NAA. Causative Microorganisms and Antibiotics Susceptibilities in Children with Urinary Tract Infection. Al-Mustansiriyah J Sci 2021;32(1):5. https://www.researchgate.net/publication/349484270_Causative_ Microorganisms_and_Antibiotics_Susceptibilities_in_Children_ with_Urinary_Tract_Infection
- Akpan A, Morgan R. Oral candidiasis. Postgrad Med J 2002; 78(922):455-9. (PMID: 12185216)
- Al-Badri AS, Ali EN, Ali Ajah HH, Ali Ajah HH. Effect of *IL-23 Receptor* Gene Polymorphism (Rs1884444) on the Prevalence of Oral Fungal Infection in Patients with Type 2 Diabetes Mellitus: A Case-Control Study in Iraqi Patients. Arch Razi Inst 2022; 77(5):1553-60. (PMID: 37123139)
- Eghtedar Nejad E, Ghasemi Nejad Almani P, Mohammadi MA, Salari S. Molecular identification of *Candida* isolates by Realtime PCR-high-resolution melting analysis and investigation of the genetic diversity of *Candida* species. J Clin Lab Anal 2020; 34(10):e23444. (PMID: 32656934)
- Amona FM, Wend-Lasida Ouedraogo R, Sangare I, Elola A. The Role of *Candida* Albicans in Routine Clinically Suspected Otomycosis. West Afr J Med 2021;38(8):743-8. (PMID: 34499919)
- Abid SA, Aziz SN, Saeed NAAA, et al. Investigation of Virulence Factors in Microbial Organisms that Associated with Public Health Risk Isolates from Different Environmental Regions. Al-Mustansiriyah J Sci 2023;33(5):1-7. https://mjs.uomustansiriyah.edu.iq/index.php/MJS/article/view/13 03
- Cerminati S, Paoletti L, Aguirre A, Peirú S, Menzella HG, Castelli ME. Industrial uses of phospholipases: current state and future applications. Appl Microbiol Biotechnol 2019;103(6): 2571-82. (PMID: 30729255)
- Ali Hameed Al-Dabbagh A, Ali Ajah H, Abdul Sattar Salman J. Detection of Virulence Factors from *Candida* spp. Isolated from Oral and Vaginal Candidiasis in Iraqi Patients. Arch Razi Inst 2023;78(1):465-74. (PMID: 37312700)
- Yin P, Peter A, Franken H, et al. Preanalytical aspects and sample quality assessment in metabolomics studies of human blood. Clin Chem 2013;59(5):833-45. (PMID: 23386698)
- Fule SR, Das D, Fule RP. Detection of phospholipase activity of *Candida* albicans and non albicans isolated from women of reproductive age with vulvovaginal candidiasis in rural area. Indian J Med Microbiol 2015;33(1):92-5. (PMID: 25560009)
- Tartor YH, Elmowalid GA, Hassan MN, Shaker A, Ashour DF, Saber T. Promising Anti-Biofilm Agents and Phagocytes Enhancers for the Treatment of *Candida albicans* Biofilm-Associated Infections. Front Cell Infect Microbiol 2022;12:807218. (PMID: 35846767)
- Vecchione A, Florio W, Celandroni F, Barnini S, Lupetti A, Ghelardi E. Comparative evaluation of six chromogenic media for presumptive yeast identification. J Clin Pathol 2017;70(12): 1074-8. (PMID: 28663328)
- Mulet Bayona JV, Salvador García C, Tormo Palop N, Gimeno Cardona C. Evaluation of a novel chromogenic medium for *Candida* spp. identification and comparison with CHROMagar[™] *Candida* for the detection of *Candida* auris in surveillance samples. Diagn Microbiol Infect Dis 2020;98(4):115168. (PMID: 32927410)

- Ajah HA, Hassan AS, Rahi GK. Isolation and Identification of *Candida* Species from oral and vaginal and determination of virulence factor. Plant Arch 2020;20(1):2697-706. https://www.plantarchives.org/20-1/2697-2706%20(6014).pdf
- Mohammed NA, Ajah HA, Abdulbaqi NJ. Detection the prevalence of adhesins and extracellular hydrolytic enzymes genes in *Candida* albicans biofilm formation. Iraqi J Sci 2017;58(2):988-1000. https://iis.uobaghdad.edu.ig/index.php/eiis/article/view/5931/

https://ijs.uobaghdad.edu.iq/index.php/eijs/article/view/5931/ 1870

- Matare T, Nziramasanga P, Gwanzura L, Robertson V. Experimental Germ Tube Induction in *Candida albicans*: An Evaluation of the Effect of Sodium Bicarbonate on Morphogenesis and Comparison with Pooled Human Serum. Biomed Res Int 2017;2017: 1976273. (PMID: 28656137)
- Deorukhkar SC, Santosh S, Jadhav P. Evaluation of different media for germ tube production of *Candida albicans* and *Candida dubliniensis*. Int J Biomed Adv Research 2012;3(9):704-7. https://www.researchgate.net/publication/272761632_EVALUAT ION_OF_DIFFERENT_MEDIA_FOR_GERM_TUBE_PRODU CTION_OF_CANDIDA_ALBICANS_AND_CANDIDA_DUBL INIENSIS
- Larkin E, Hager C, Chandra J, et al. The Emerging Pathogen Candida auris: Growth Phenotype, Virulence Factors, Activity of Antifungals, and Effect of SCY-078, a Novel Glucan Synthesis Inhibitor, on Growth Morphology and Biofilm Formation. Antimicrob Agents Chemother 2017;61(5):e02396-16. (PMID: 28223375)
- de Paula Menezes R, de Melo Riceto ÉB, Borges AS, de Brito Röder DVD, dos Santos Pedroso R. Evaluation of virulence factors of *Candida* albicans isolated from HIV-positive individuals using HAART. Arch Oral Biol 2016;66:61-5. (PMID: 26913969)
- Mba IE, Nweze EI. Mechanism of *Candida* pathogenesis: revisiting the vital drivers. Eur J Clin Microbiol Infect Dis 2020;39(10): 1797-819. (PMID: 32372128)
- 23. Jawdat S. Determination of some virulence factors of *Candida* spp. isolated from locally produced cheese in Diyala Governor-ate-Iraq. Al-Mustansiriyah J Sci 2017;27(4):1-6. https://www.researchgate.net/publication/314129240_Determinat ion_of_some_virulence_factors_of_Candida_spp_isolated_from_locally_produced_cheese_in_Diyala_Governorate-Iraq